<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">92311</article-id><article-id pub-id-type="doi">10.7554/eLife.92311</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.92311.3</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Replication of null results: Absence of evidence or evidence of absence?</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-318579"><name><surname>Pawel</surname><given-names>Samuel</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2779-320X</contrib-id><email>samuel.pawel@uzh.ch</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-318716"><name><surname>Heyard</surname><given-names>Rachel</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7531-4333</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-318717"><name><surname>Micheloud</surname><given-names>Charlotte</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4995-4505</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-281714"><name><surname>Held</surname><given-names>Leonhard</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8686-5325</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02crff812</institution-id><institution>Epidemiology, Biostatistics and Prevention Institute, Center for Reproducible Science, University of Zurich</institution></institution-wrap><addr-line><named-content content-type="city">Zurich</named-content></addr-line><country>Switzerland</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Boonstra</surname><given-names>Philip</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00jmfr291</institution-id><institution>University of Michigan</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Rodgers</surname><given-names>Peter</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04rjz5883</institution-id><institution>eLife</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>13</day><month>05</month><year>2024</year></pub-date><volume>12</volume><elocation-id>RP92311</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-09-08"><day>08</day><month>09</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-05-08"><day>08</day><month>05</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.48550/arXiv.2305.04587"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-11-22"><day>22</day><month>11</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.92311.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-02-16"><day>16</day><month>02</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.92311.2"/></event></pub-history><permissions><copyright-statement>© 2023, Pawel, Heyard et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Pawel, Heyard et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-92311-v1.pdf"/><abstract><p>In several large-scale replication projects, statistically non-significant results in both the original and the replication study have been interpreted as a ‘replication success.’ Here, we discuss the logical problems with this approach: Non-significance in both studies does not ensure that the studies provide evidence for the absence of an effect and ‘replication success’ can virtually always be achieved if the sample sizes are small enough. In addition, the relevant error rates are not controlled. We show how methods, such as equivalence testing and Bayes factors, can be used to adequately quantify the evidence for the absence of an effect and how they can be applied in the replication setting. Using data from the Reproducibility Project: Cancer Biology, the Experimental Philosophy Replicability Project, and the Reproducibility Project: Psychology we illustrate that many original and replication studies with ‘null results’ are in fact inconclusive. We conclude that it is important to also replicate studies with statistically non-significant results, but that they should be designed, analyzed, and interpreted appropriately.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>Bayesian hypothesis testing</kwd><kwd>equivalence testing</kwd><kwd>meta-research</kwd><kwd>null hypothesis</kwd><kwd>replication success</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>None</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001711</institution-id><institution>Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung</institution></institution-wrap></funding-source><award-id>189295</award-id><principal-award-recipient><name><surname>Held</surname><given-names>Leonhard</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Equivalence testing and Bayes factors are informative statistical methods for analyzing replication studies of original studies with null results, and can address the limitations of the commonly used non-significance criterion.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p><italic>Absence of evidence is not evidence of absence</italic> – the title of the 1995 paper by Douglas Altman and Martin Bland has since become a mantra in the statistical and medical literature (<xref ref-type="bibr" rid="bib1">Altman and Bland, 1995</xref>). Yet, the misconception that a statistically non-significant result indicates evidence for the absence of an effect is unfortunately still widespread (<xref ref-type="bibr" rid="bib21">Greenland, 2011</xref>; <xref ref-type="bibr" rid="bib42">Makin and Orban de Xivry, 2019</xref>). Such a ‘null result’ – typically characterized by a <italic>p</italic>-value <inline-formula><mml:math id="inf1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>p</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0.05</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> for the null hypothesis of an absent effect – may also occur if an effect is actually present. For example, if the sample size of a study is chosen to detect an assumed effect with a power of 80%, null results will incorrectly occur 20% of the time when the assumed effect is actually present. If the power of the study is lower, null results will occur more often. In general, the lower the power of a study, the greater the ambiguity of a null result. To put a null result in context, it is, therefore, critical to know whether the study was adequately powered and under what assumed effect the power was calculated (<xref ref-type="bibr" rid="bib27">Hoenig and Heisey, 2001</xref>; <xref ref-type="bibr" rid="bib22">Greenland, 2012</xref>). However, if the goal of a study is to explicitly quantify the evidence for the absence of an effect, more appropriate methods designed for this task, such as equivalence testing (<xref ref-type="bibr" rid="bib66">Wellek, 2010</xref>; <xref ref-type="bibr" rid="bib37">Lakens, 2017</xref>; <xref ref-type="bibr" rid="bib62">Senn, 2021</xref>) or Bayes factors (<xref ref-type="bibr" rid="bib31">Kass and Raftery, 1995</xref>; <xref ref-type="bibr" rid="bib19">Goodman, 1999</xref>; <xref ref-type="bibr" rid="bib20">Goodman, 2005</xref>; <xref ref-type="bibr" rid="bib14">Dienes, 2014</xref>; <xref ref-type="bibr" rid="bib33">Keysers et al., 2020</xref>), should be used from the outset.</p><p>The interpretation of null results becomes even more complicated in the setting of replication studies. In a replication study, researchers attempt to repeat an original study as closely as possible in order to assess whether consistent results can be obtained with new data (<xref ref-type="bibr" rid="bib50">National Academies of Sciences, Engineering, and Medicine, 2019</xref>). In the last decade, various large-scale replication projects have been conducted in diverse fields, from the biomedical to the social sciences (<xref ref-type="bibr" rid="bib55">Prinz et al., 2011</xref>; <xref ref-type="bibr" rid="bib5">Begley and Ellis, 2012</xref>; <xref ref-type="bibr" rid="bib34">Klein et al., 2014</xref>; <xref ref-type="bibr" rid="bib51">Open Science Collaboration, 2015</xref>; <xref ref-type="bibr" rid="bib6">Camerer et al., 2016</xref>; <xref ref-type="bibr" rid="bib7">Camerer et al., 2018</xref>; <xref ref-type="bibr" rid="bib35">Klein et al., 2018</xref>; <xref ref-type="bibr" rid="bib12">Cova et al., 2021</xref>; <xref ref-type="bibr" rid="bib16">Errington et al., 2021</xref>, among others). The majority of these projects reported alarmingly low replicability rates across a broad spectrum of criteria for quantifying replicability. While most of these projects restricted their focus on original studies with statistically significant results (‘positive results’), the <italic>Reproducibility Project: Cancer Biology</italic> (RPCB, <xref ref-type="bibr" rid="bib16">Errington et al., 2021</xref>), the <italic>Experimental Philosophy Replicability Project</italic> (EPRP, <xref ref-type="bibr" rid="bib12">Cova et al., 2021</xref>), and the <italic>Reproducibility Project: Psychology</italic> (RPP, <xref ref-type="bibr" rid="bib51">Open Science Collaboration, 2015</xref>) also attempted to replicate some original studies with null results – either non-significant or interpreted as showing no evidence for a meaningful effect by the original authors.</p><p>Although the EPRP and RPP interpreted non-significant results in both original and replication studies as a ‘replication success’ for some individual replications (see, for example, the replication of <xref ref-type="bibr" rid="bib46">McCann, 2005</xref>, replication report: <ext-link ext-link-type="uri" xlink:href="https://osf.io/wcm7n">https://osf.io/wcm7n</ext-link>, or the replication of <xref ref-type="bibr" rid="bib56">Ranganath and Nosek, 2008</xref>, replication report: <ext-link ext-link-type="uri" xlink:href="https://osf.io/9xt25">https://osf.io/9xt25</ext-link>), they excluded the original null results in the calculation of an overall replicability rate based on significance. In contrast, the RPCB explicitly defined null results in both the original and the replication study as a criterion for ‘replication success.’ According to this ‘non-significance’ criterion, 11/15=73% replications of original null effects were successful. Four additional criteria were used to provide a more nuanced assessment of replication success for original null results: (i) whether the original effect estimate was included in the 95% confidence interval of the replication effect estimate (success rate 11/15=73%), (ii) whether the replication effect estimate was included in the 95% confidence interval of the original effect estimate (success rate 12/15=80%), (iii) whether the replication effect estimate was included in the 95% prediction interval based on the original effect estimate (success rate 12/15=80%), (iv) and whether the <italic>p</italic>-value obtained from combining the original and replication effect estimate with a meta-analysis was non-significant (success rate 10/15=67%). Criteria (i) to (iii) are useful for assessing compatibility in effect estimates between the original and the replication study. Their suitability has been extensively discussed in the literature. The prediction interval criterion (iii) or equivalent criteria (e.g. the <inline-formula><mml:math id="inf2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>Q</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>-test) are usually recommended because they account for the uncertainty from both studies and have adequate error rates when the true effect sizes are the same (<xref ref-type="bibr" rid="bib52">Patil et al., 2016</xref>; <xref ref-type="bibr" rid="bib43">Mathur and VanderWeele, 2020</xref>; <xref ref-type="bibr" rid="bib60">Schauer and Hedges, 2021</xref>).</p><p>While the effect estimate criteria (i) to (iii) can be applied regardless of whether or not the original study was non-significant, the ‘meta-analytic non-significance’ criterion (iv) and the aforementioned non-significance criterion refer specifically to original null results. We believe that there are several logical problems with both, and that it is important to highlight and address them, especially since the non-significance criterion has already been used in three replication projects without much scrutiny. It is crucial to note that it is not our intention to diminish the enormously important contributions of the RPCB, the EPRP, and the RPP, but rather to build on their work and provide recommendations for ongoing and future replication projects (e.g. <xref ref-type="bibr" rid="bib2">Amaral et al., 2019</xref>; <xref ref-type="bibr" rid="bib49">Murphy et al., 2023</xref>).</p><p>The logical problems with the non-significance criterion are as follows: First, if the original study had low statistical power, a non-significant result is highly inconclusive and does not provide evidence for the absence of an effect. It is then unclear what exactly the goal of the replication should be – to replicate the inconclusiveness of the original result? On the other hand, if the original study was adequately powered, a non-significant result may indeed provide some evidence for the absence of an effect when analyzed with appropriate methods, so that the goal of the replication is clearer. However, the criterion by itself does not distinguish between these two cases. Second, with this criterion researchers can virtually always achieve replication success by conducting a replication study with a very small sample size, such that the <italic>p</italic>-value is non-significant and the result is inconclusive. This is because the null hypothesis under which the <italic>p</italic>-value is computed is misaligned with the goal of inference, which is to quantify the evidence for the absence of an effect. Third, the criterion does not control the error of falsely claiming the absence of an effect at a predetermined rate. This is in contrast to the standard criterion for replication success, which requires significance from both studies (also known as the two-trials rule, see Section 12.2.8 in <xref ref-type="bibr" rid="bib62">Senn, 2021</xref>), and ensures that the error of falsely claiming the presence of an effect is controlled at a rate equal to the squared significance level (for example, 5% × 5%=0.25% for a 5% significance level). The non-significance criterion may be intended to complement the two-trials rule for null results. However, it fails to do so in this respect, which may be required by regulators and funders. These logical problems are equally applicable to the meta-analytic non-significance criterion.</p><p>In the following, we present two principled approaches for analyzing replication studies of null results – frequentist equivalence testing and Bayesian hypothesis testing – that can address the limitations of the non-significance criterion. We use the null results replicated in the RPCB, RPP, and EPRP to illustrate the problems of the non-significance criterion and how they can be addressed. We conclude the paper with practical recommendations for analyzing replication studies of original null results, including simple R code for applying the proposed methods.</p></sec><sec id="s2"><title>Null results from the Reproducibility Project: Cancer Biology</title><p><xref ref-type="fig" rid="fig1">Figure 1</xref> shows effect estimates on the standardized mean difference (SMD) scale with a 95% confidence intervals from two RPCB study pairs. In both study pairs, the original, and replication studies are ‘null results’ and, therefore, meet the non-significance criterion for replication success (the two-sided <italic>p</italic>-values are greater than 0.05 in both the original and the replication study). The same is true when applying the meta-analytic non-significance criterion (the two-sided <italic>p</italic>-values of the meta-analyses <italic>p<sub>MA</sub></italic> are greater than 0.05). However, intuition would suggest that the conclusions in the two pairs are very different.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Two examples of original and replication study pairs which meet the non-significance replication success criterion from the Reproducibility Project: Cancer Biology (<xref ref-type="bibr" rid="bib16">Errington et al., 2021</xref>).</title><p>Shown are standardized mean difference effect estimates with 95% confidence intervals, sample sizes <italic>n</italic>, and two-sided <italic>p</italic>-values <italic>p</italic> for the null hypothesis that the effect is absent. Effect estimate, 95% confidence interval, and <italic>p</italic>-value from a fixed-effect meta-analysis <italic>p<sub>MA</sub></italic> of original and replication study are shown in gray.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92311-fig1-v1.tif"/></fig><p>The original study from <xref ref-type="bibr" rid="bib13">Dawson et al., 2011</xref> and its replication both show large effect estimates in magnitude, but due to the very small sample sizes, the uncertainty of these estimates is large, too. With such low sample sizes, the results seem inconclusive. In contrast, the effect estimates from <xref ref-type="bibr" rid="bib18">Goetz et al., 2011</xref> and its replication are much smaller in magnitude and their uncertainty is also smaller because the studies used larger sample sizes. Intuitively, the results seem to provide more evidence for a zero (or negligibly small) effect. While these two examples show the qualitative difference between the absence of evidence and evidence of absence, we will now discuss how the two can be quantitatively distinguished.</p></sec><sec id="s3"><title>Methods for assessing replicability of null results</title><p>There are both frequentist and Bayesian methods that can be used for assessing evidence for the absence of an effect. <xref ref-type="bibr" rid="bib3">Anderson and Maxwell, 2016</xref> provide an excellent summary in the context of replication studies in psychology. We now briefly discuss two possible approaches – frequentist equivalence testing and Bayesian hypothesis testing – and their application to the RPCB, EPRP, and RPP data.</p><sec id="s3-1"><title>Frequentist equivalence testing</title><p>Equivalence testing was developed in the context of clinical trials to assess whether a new treatment – typically cheaper or with fewer side effects than the established treatment – is practically equivalent to the established treatment (<xref ref-type="bibr" rid="bib66">Wellek, 2010</xref>; <xref ref-type="bibr" rid="bib37">Lakens, 2017</xref>). The method can also be used to assess whether an effect is practically equivalent to an absent effect, usually zero. Using equivalence testing as a way to put non-significant results into context has been suggested by several authors (<xref ref-type="bibr" rid="bib24">Hauck and Anderson, 1986</xref>; <xref ref-type="bibr" rid="bib8">Campbell and Gustafson, 2018</xref>). The main challenge is to specify the margin <inline-formula><mml:math id="inf3"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi mathvariant="normal">Δ</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> that defines an equivalence range <inline-formula><mml:math id="inf4"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">[</mml:mo><mml:mo>−</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi><mml:mo>,</mml:mo><mml:mo>+</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi><mml:mo stretchy="false">]</mml:mo></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> in which an effect is considered as absent for practical purposes. The goal is then to reject the null hypothesis that the true effect is outside the equivalence range. This is in contrast to the usual null hypotheses of superiority tests which state that the effect is zero or smaller than zero, see <xref ref-type="fig" rid="fig2">Figure 2</xref> for an illustration.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Null hypothesis (<inline-formula><mml:math id="inf5"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>) and alternative hypothesis (<inline-formula><mml:math id="inf6"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>) for superiority and equivalence tests (with equivalence margin <inline-formula><mml:math id="inf7"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi mathvariant="normal">Δ</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>).</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92311-fig2-v1.tif"/></fig><p>To ensure that the null hypothesis is falsely rejected at most <inline-formula><mml:math id="inf8"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>α</mml:mi><mml:mo>×</mml:mo><mml:mn>100</mml:mn><mml:mi mathvariant="normal">%</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> of the time, the standard approach is to declare equivalence if the <inline-formula><mml:math id="inf9"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:mi>α</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>×</mml:mo><mml:mn>100</mml:mn><mml:mi mathvariant="normal">%</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> confidence interval for the effect is contained within the equivalence range, for example, a 90% confidence interval for <inline-formula><mml:math id="inf10"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>α</mml:mi><mml:mo>=</mml:mo><mml:mn>0.05</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> (<xref ref-type="bibr" rid="bib67">Westlake, 1972</xref>). This procedure is equivalent to declaring equivalence when two one-sided tests (TOST) for the null hypotheses of the effect being greater/smaller than <inline-formula><mml:math id="inf11"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo>+</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf12"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo>−</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>, are both significant at level α (<xref ref-type="bibr" rid="bib61">Schuirmann, 1987</xref>). A quantitative measure of evidence for the absence of an effect is then given by the maximum of the two one-sided <italic>p</italic>-values – the TOST <italic>p</italic>-value (<xref ref-type="bibr" rid="bib23">Greenland, 2023</xref>, section 4.4). In case a dichotomous replication success criterion for null results is desired, it is natural to require that both the original and the replication TOST <italic>p</italic>-values are smaller than some level α (conventionally <inline-formula><mml:math id="inf13"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>α</mml:mi><mml:mo>=</mml:mo><mml:mn>0.05</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>). Equivalently, the criterion would require the <inline-formula><mml:math id="inf14"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:mi>α</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>×</mml:mo><mml:mn>100</mml:mn><mml:mi mathvariant="normal">%</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> confidence intervals of the original and the replication to be included in the equivalence region. In contrast to the non-significance criterion, this criterion controls the error of falsely claiming replication success at level <inline-formula><mml:math id="inf15"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msup><mml:mi>α</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> when there is a true effect outside the equivalence margin, thus complementing the usual two-trials rule in drug regulation (<xref ref-type="bibr" rid="bib62">Senn, 2021</xref>, Section 12.2.8).</p><p>Returning to the RPCB data, <xref ref-type="fig" rid="fig3">Figure 3</xref> shows the standardized mean difference effect estimates with 90% confidence intervals for all 15 effects which were treated as null results by the RPCB. [There are four original studies with null effects for which two or three ‘internal’ replication studies were conducted, leading in total to 20 replications of null effects. As done in the RPCB main analysis (<xref ref-type="bibr" rid="bib16">Errington et al., 2021</xref>), we aggregated their SMD estimates into a single SMD estimate with fixed-effect meta-analysis and recomputed the replication <italic>p</italic>-value based on a normal approximation. For the original studies and the single replication studies we report the SMD estimates and <italic>p</italic>-values as provided by the RPCB]. Most of them showed non-significant <italic>p</italic>-values (<inline-formula><mml:math id="inf16"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>p</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0.05</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>) in the original study. It is noteworthy, however, that two effects from the second experiment of the original paper 48 were regarded as null results despite their statistical significance. According to the non-significance criterion (requiring <inline-formula><mml:math id="inf17"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>p</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0.05</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> in original and replication study), there are 11 ‘successes’ out of total 15 null effects, as reported in Table 1 from <xref ref-type="bibr" rid="bib16">Errington et al., 2021</xref>.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Effect estimates on the standardized mean difference (SMD) scale with 90% confidence interval for the 15 ‘null results’ and their replication studies from the Reproducibility Project: Cancer Biology (<xref ref-type="bibr" rid="bib16">Errington et al., 2021</xref>).</title><p>The title above each plot indicates the original paper, experiment and effect numbers. Two original effect estimates from original paper 48 were statistically significant at <inline-formula><mml:math id="inf18"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.05</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>, but were interpreted as null results by the original authors and, therefore, treated as null results by the RPCB. The two examples from <xref ref-type="fig" rid="fig1">Figure 1</xref> are indicated in the plot titles. The dashed gray line represents the value of no effect (<inline-formula><mml:math id="inf19"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mtext>SMD</mml:mtext><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>), while the dotted red lines represent the equivalence range with a margin of <inline-formula><mml:math id="inf20"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi mathvariant="normal">Δ</mml:mi><mml:mo>=</mml:mo><mml:mn>0.74</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>, classified as ‘liberal’ by <xref ref-type="bibr" rid="bib66">Wellek, 2010</xref>, Table 1.1. The <italic>p</italic>-value <inline-formula><mml:math id="inf21"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mtext> </mml:mtext><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mtext>TOST</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> is the maximum of the two one-sided <italic>p</italic>-values for the null hypotheses of the effect being greater/less than <inline-formula><mml:math id="inf22"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo>+</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf23"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo>−</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>, respectively. The Bayes factor <inline-formula><mml:math id="inf24"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>BF</mml:mi><mml:mrow><mml:mn>01</mml:mn></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> quantifies the evidence for the null hypothesis <inline-formula><mml:math id="inf25"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>:</mml:mo><mml:mtext>SMD</mml:mtext><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> against the alternative <inline-formula><mml:math id="inf26"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>:</mml:mo><mml:mtext>SMD</mml:mtext><mml:mo>≠</mml:mo><mml:mn>0</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> with normal unit-information prior assigned to the SMD under <inline-formula><mml:math id="inf27"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92311-fig3-v1.tif"/></fig><p>We will now apply equivalence testing to the RPCB data. The dotted red lines in <xref ref-type="fig" rid="fig3">Figure 3</xref> represent an equivalence range for the margin <inline-formula><mml:math id="inf28"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi mathvariant="normal">Δ</mml:mi><mml:mo>=</mml:mo><mml:mn>0.74</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>, which (<xref ref-type="bibr" rid="bib66">Wellek, 2010</xref>, Table 1.1) classifies as ‘liberal.’ However, even with this generous margin, only 4 of the 15 study pairs are able to establish replication success at the 5% level, in the sense that both the original and the replication 90% confidence interval fall within the equivalence range (or, equivalently, that their TOST <italic>p</italic>-values are smaller than 0.05). For the remaining 11 studies, the situation remains inconclusive and there is no evidence for the absence or the presence of the effect. For instance, the previously discussed example from <xref ref-type="bibr" rid="bib18">Goetz et al., 2011</xref> marginally fails the criterion (<inline-formula><mml:math id="inf29"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mtext>TOST</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.06</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> in the original study and <inline-formula><mml:math id="inf30"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mtext>TOST</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.04</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> in the replication), while the example from <xref ref-type="bibr" rid="bib13">Dawson et al., 2011</xref> is a clearer failure (<inline-formula><mml:math id="inf31"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mtext>TOST</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.75</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> in the original study and <inline-formula><mml:math id="inf32"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mtext>TOST</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.88</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> in the replication) as both effect estimates even lie outside the equivalence margin.</p><p>The post-hoc specification of equivalence margins is controversial. Ideally, the margin should be specified on a case-by-case basis in a pre-registered protocol before the studies are conducted by researchers familiar with the subject matter. In the social and medical sciences, the conventions of <xref ref-type="bibr" rid="bib10">Cohen, 1992</xref> are typically used to classify SMD effect sizes (<inline-formula><mml:math id="inf33"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mtext>SMD</mml:mtext><mml:mo>=</mml:mo><mml:mn>0.2</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> small, <inline-formula><mml:math id="inf34"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mtext>SMD</mml:mtext><mml:mo>=</mml:mo><mml:mn>0.5</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> medium, <inline-formula><mml:math id="inf35"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mtext>SMD</mml:mtext><mml:mo>=</mml:mo><mml:mn>0.8</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> large). While effect sizes are typically larger in preclinical research, it seems unrealistic to specify margins larger than 1 on the SMD scale to represent effect sizes that are absent for practical purposes. It could also be argued that the chosen margin <inline-formula><mml:math id="inf36"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi mathvariant="normal">Δ</mml:mi><mml:mo>=</mml:mo><mml:mn>0.74</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> is too lax compared to margins commonly used in clinical research (<xref ref-type="bibr" rid="bib38">Lange and Freitag, 2005</xref>). We, therefore, report a sensitivity analysis regarding the choice of the margin in <xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1</xref>. This analysis shows that for realistic margins between 0 and 1, the proportion of replication successes remains below 50% for the conventional <inline-formula><mml:math id="inf37"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>α</mml:mi><mml:mo>=</mml:mo><mml:mn>0.05</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> level. To achieve a success rate of 11/15=73%, as was achieved with the non-significance criterion from the RPCB, unrealistic margins of <inline-formula><mml:math id="inf38"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi mathvariant="normal">Δ</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>2</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> are required.</p><p>Appendix 2 shows similar equivalence test analyses for the four study pairs with original null results from the RPP and EPRP. Three study pair results turn out to be inconclusive due to the large uncertainty around their effect estimates.</p></sec><sec id="s3-2"><title>Bayesian hypothesis testing</title><p>The distinction between absence of evidence and evidence of absence is naturally built into the Bayesian approach to hypothesis testing. A central measure of evidence is the Bayes factor (<xref ref-type="bibr" rid="bib31">Kass and Raftery, 1995</xref>; <xref ref-type="bibr" rid="bib19">Goodman, 1999</xref>; <xref ref-type="bibr" rid="bib14">Dienes, 2014</xref>; <xref ref-type="bibr" rid="bib33">Keysers et al., 2020</xref>), which is the updating factor of the prior odds to the posterior odds of the null hypothesis <inline-formula><mml:math id="inf39"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> versus the alternative hypothesis <inline-formula><mml:math id="inf40"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula><disp-formula id="equ1"><mml:math id="m1"><mml:mrow><mml:munder><mml:mrow><mml:munder><mml:mfrac><mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mtext> </mml:mtext><mml:mrow><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mtext> </mml:mtext><mml:mrow><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mo>⏟</mml:mo></mml:munder></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:mrow></mml:munder><mml:mo>=</mml:mo><mml:munder><mml:mrow><mml:munder><mml:mfrac><mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mo>⏟</mml:mo></mml:munder></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:mrow></mml:munder><mml:mo>×</mml:mo><mml:munder><mml:mrow><mml:munder><mml:mfrac><mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mspace width="thinmathspace"/></mml:mrow><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mspace width="thinmathspace"/></mml:mrow><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mo>⏟</mml:mo></mml:munder></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">y</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mspace width="thinmathspace"/></mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">F</mml:mi></mml:mrow><mml:mrow><mml:mn>01</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:munder><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>The Bayes factor <inline-formula><mml:math id="inf41"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>BF</mml:mi><mml:mrow><mml:mn>01</mml:mn></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> quantifies how much the observed data have increased or decreased the probability <inline-formula><mml:math id="inf42"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo movablelimits="true" form="prefix">Pr</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> of the null hypothesis relative to the probability <inline-formula><mml:math id="inf43"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo movablelimits="true" form="prefix">Pr</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> of the alternative. As such, Bayes factors are direct measures of evidence for the null hypothesis, in contrast to <italic>p</italic>-values, which are only indirect measures of evidence as they are computed under the assumption that the null hypothesis is true (<xref ref-type="bibr" rid="bib25">Held and Ott, 2018</xref>). If the null hypothesis states the absence of an effect, a Bayes factor greater than one (<inline-formula><mml:math id="inf44"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>BF</mml:mi><mml:mrow><mml:mn>01</mml:mn></mml:mrow></mml:msub><mml:mo>&gt;</mml:mo><mml:mn>1</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>) indicates evidence for the absence of the effect and a Bayes factor smaller than one indicates evidence for the presence of the effect (<inline-formula><mml:math id="inf45"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>BF</mml:mi><mml:mrow><mml:mn>01</mml:mn></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:mn>1</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>), whereas a Bayes factor not much different from one indicates absence of evidence for either hypothesis (<inline-formula><mml:math id="inf46"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>BF</mml:mi><mml:mrow><mml:mn>01</mml:mn></mml:mrow></mml:msub><mml:mo>≈</mml:mo><mml:mn>1</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>). Bayes factors are quantitative summaries of the evidence provided by the data in favor of the null hypothesis as opposed to the alternative hypothesis. However, if a dichotomous criterion for successful replication of a null result is desired, it seems natural to require a Bayes factor larger than some level <inline-formula><mml:math id="inf47"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>γ</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>1</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> from both studies, for example, <inline-formula><mml:math id="inf48"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>γ</mml:mi><mml:mo>=</mml:mo><mml:mn>3</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> or <inline-formula><mml:math id="inf49"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>γ</mml:mi><mml:mo>=</mml:mo><mml:mn>10</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> which are conventional levels for ‘substantial’ and ‘strong’ evidence, respectively (<xref ref-type="bibr" rid="bib29">Jeffreys, 1961</xref>). In contrast to the non-significance criterion, this criterion provides a genuine measure of evidence that can distinguish absence of evidence from evidence of absence.</p><p>The main challenge with Bayes factors is the specification of the effect under the alternative hypothesis <inline-formula><mml:math id="inf50"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>. The assumed effect under <inline-formula><mml:math id="inf51"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> is directly related to the Bayes factor, and researchers who assume different effects will end up with different Bayes factors. Instead of specifying a single effect, one therefore typically specifies a ‘prior distribution’ of plausible effects. Importantly, the prior distribution, like the equivalence margin, should be determined by researchers with subject knowledge and before the data are collected.</p><p>To compute the Bayes factors for the RPCB null results, we used the observed effect estimates as the data and assumed a normal sampling distribution for them (<xref ref-type="bibr" rid="bib14">Dienes, 2014</xref>), as typically done in a meta-analysis. The Bayes factors <inline-formula><mml:math id="inf52"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>BF</mml:mi><mml:mrow><mml:mn>01</mml:mn></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> shown in <xref ref-type="fig" rid="fig3">Figure 3</xref> then quantify the evidence for the null hypothesis of no effect against the alternative hypothesis that there is an effect using a normal ‘unit-information’ prior distribution (<xref ref-type="bibr" rid="bib32">Kass and Wasserman, 1995</xref>) for the effect size under the alternative <inline-formula><mml:math id="inf53"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>, see Appendix 3 for further details on the calculation of these Bayes factors. We see that in most cases there is no substantial evidence for either the absence or the presence of an effect, as with the equivalence tests. For instance, with a lenient Bayes factor threshold of 3, only 1 of the 15 replications are successful, in the sense of having <inline-formula><mml:math id="inf54"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>BF</mml:mi><mml:mrow><mml:mn>01</mml:mn></mml:mrow></mml:msub><mml:mo>&gt;</mml:mo><mml:mn>3</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> in both the original and the replication study. The Bayes factors for the two previously discussed examples are consistent with our intuitions – in the <xref ref-type="bibr" rid="bib18">Goetz et al., 2011</xref> example there is indeed substantial evidence for the absence of an effect (<inline-formula><mml:math id="inf55"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>BF</mml:mi><mml:mrow><mml:mn>01</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>5</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> in the original study and <inline-formula><mml:math id="inf56"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>BF</mml:mi><mml:mrow><mml:mn>01</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>4.1</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> in the replication), while in the <xref ref-type="bibr" rid="bib13">Dawson et al., 2011</xref> example there is even anecdotal evidence for the <italic>presence</italic> of an effect, though the Bayes factors are very close to one due to the small sample sizes (<inline-formula><mml:math id="inf57"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>BF</mml:mi><mml:mrow><mml:mn>01</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>1.1</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> in the original study and <inline-formula><mml:math id="inf58"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>BF</mml:mi><mml:mrow><mml:mn>01</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>1.8</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> in the replication).</p><p>As with the equivalence margin, the choice of the prior distribution for the SMD under the alternative <inline-formula><mml:math id="inf59"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> is debatable. The normal unit-information prior seems to be a reasonable default choice, as it implies that small to large effects are plausible under the alternative, but other normal priors with smaller/larger standard deviations could have been considered to make the test more sensitive to smaller/larger true effect sizes. The sensitivity analysis in Appendix 1, therefore, also includes an analysis on the effect of varying prior standard deviations and the Bayes factor thresholds. However, again, to achieve replication success for a larger proportion of replications than the observed 1/15=7%, unreasonably large prior standard deviations have to be specified.</p><p>Of note, among the 15 RPCB null results, there are three interesting cases (the three effects from original paper 48 by <xref ref-type="bibr" rid="bib40">Lin et al., 2012</xref> and its replication by <xref ref-type="bibr" rid="bib39">Lewis et al., 2018</xref>) where the Bayes factor is qualitatively different from the equivalence test, revealing a fundamental difference between the two approaches. The Bayes factor is concerned with testing whether the effect is <italic>exactly zero</italic>, whereas the equivalence test is concerned with whether the effect is within an <italic>interval around zero</italic>. Due to the very large sample size in the original study (n=514) and the replication (n=1153), the data are incompatible with an exactly zero effect, but compatible with effects within the equivalence range. Apart from this example, however, both approaches lead to the same qualitative conclusion – most RPCB null results are highly ambiguous.</p><p>Appendix 2 also shows Bayes factor analyses for the four study pairs with original null results from the RPP and EPRP. In contrast to the RPCB results, most Bayes factors indicate non-anecdotal evidence for a null effect in cases where the non-significance criterion was met, possibly because of the larger sample sizes and smaller effects in these fields.</p></sec><sec id="s3-3"><title>Conclusions</title><p>The concept of ‘replication success’ is inherently multifaceted. Reducing it to a single criterion seems to be an oversimplification. Nevertheless, we believe that the ‘non-significance’ criterion – declaring a replication as successful if both the original and the replication study produce non-significant results – is not fit for purpose. This criterion does not ensure that both studies provide evidence for the absence of an effect, it can be easily achieved for any outcome if the studies have sufficiently small sample sizes, and it does not control the relevant error rates. While it is important to replicate original studies with null results, we believe that they should be analyzed using more informative approaches. <xref ref-type="box" rid="box1">Box 1</xref> summarizes our recommendations.</p><boxed-text id="box1"><label>Box 1.</label><caption><title>Recommendations for the analysis of replication studies of original null results.</title></caption><p>Calculations are based on effect estimates <inline-formula><mml:math id="inf60"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mrow><mml:mover><mml:mi>θ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> with standard errors <inline-formula><mml:math id="inf61"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>σ</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> from an original study (<inline-formula><mml:math id="inf62"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mi>o</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>) and its replication (<inline-formula><mml:math id="inf63"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mi>r</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>). Both effect estimates are assumed to be normally distributed around the true effect size <inline-formula><mml:math id="inf64"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>θ</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> with known variance <inline-formula><mml:math id="inf65"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msubsup><mml:mi>σ</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>. The effect size <inline-formula><mml:math id="inf66"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> represents the value of no effect, typically <inline-formula><mml:math id="inf67"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>.</p><p><bold>Equivalence test</bold></p><list list-type="order"><list-item><p>Specify a margin <inline-formula><mml:math id="inf68"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi mathvariant="normal">Δ</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> that defines an equivalence range <inline-formula><mml:math id="inf69"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi><mml:mo stretchy="false">]</mml:mo></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> in which effects are considered absent for practical purposes.</p></list-item><list-item><p>Compute the TOST <italic>p</italic>-values for original (<inline-formula><mml:math id="inf70"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mi>o</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>) and replication (<inline-formula><mml:math id="inf71"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mi>r</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>) data</p></list-item></list><p><disp-formula id="equ2"><mml:math id="m2"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">T</mml:mi><mml:mi mathvariant="normal">O</mml:mi><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">T</mml:mi></mml:mrow><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo movablelimits="true" form="prefix">max</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mi mathvariant="normal">Φ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>θ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi></mml:mrow><mml:msub><mml:mi>σ</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi mathvariant="normal">Φ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>θ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi></mml:mrow><mml:msub><mml:mi>σ</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>}</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>with <inline-formula><mml:math id="inf72"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Φ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mo>⋅</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula> the cumulative distribution function of the standard normal distribution.</p><p><code xml:space="preserve">## R function to compute TOST p-value based on effect estimate, standard
## error, null value (default is 0), equivalence margin from step 1.
pTOST &lt;- function(estimate, se, null = 0, margin) {
 p1 &lt;- pnorm(q = (estimate - null - margin)/se)
 p2 &lt;- 1 - pnorm(q = (estimate - null + margin)/se)
 p &lt;- pmax(p1, p2)
 return(p)
}</code></p><list list-type="order"><list-item><p>Declare replication success at level <inline-formula><mml:math id="inf73"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>α</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> if <inline-formula><mml:math id="inf74"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mtext>TOST</mml:mtext><mml:mo>,</mml:mo><mml:mi>o</mml:mi></mml:mrow></mml:msub><mml:mo>≤</mml:mo><mml:mi>α</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf75"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mtext>TOST</mml:mtext><mml:mo>,</mml:mo><mml:mi>r</mml:mi></mml:mrow></mml:msub><mml:mo>≤</mml:mo><mml:mi>α</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>, conventionally <inline-formula><mml:math id="inf76"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>α</mml:mi><mml:mo>=</mml:mo><mml:mn>0.05</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>.</p></list-item><list-item><p>Perform a sensitivity analysis with respect to the margin <inline-formula><mml:math id="inf77"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>. For example, visualize the TOST <italic>p</italic>-values for different margins to assess the robustness of the conclusions.</p></list-item></list><p><bold>Bayes factor</bold></p><list list-type="order"><list-item><p>Specify a prior distribution for the effect size <inline-formula><mml:math id="inf78"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>θ</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> that represents plausible values under the alternative hypothesis that there is an effect <inline-formula><mml:math id="inf79"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>:</mml:mo><mml:mi>θ</mml:mi><mml:mo>≠</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>. For example, specify the mean <inline-formula><mml:math id="inf80"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> and standard deviation <inline-formula><mml:math id="inf81"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> of a normal distribution <inline-formula><mml:math id="inf82"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>θ</mml:mi><mml:mspace width="thinmathspace"/><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mspace width="thinmathspace"/><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>∼</mml:mo><mml:mi mathvariant="normal">N</mml:mi><mml:mo>⁡</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>s</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>.</p></list-item><list-item><p>Compute the Bayes factors contrasting <inline-formula><mml:math id="inf83"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>:</mml:mo><mml:mi>θ</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> to <inline-formula><mml:math id="inf84"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>:</mml:mo><mml:mi>θ</mml:mi><mml:mo>≠</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> for original (<inline-formula><mml:math id="inf85"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mi>o</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>) and replication (<inline-formula><mml:math id="inf86"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mi>r</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>) data. Assuming a normal prior distribution, the Bayes factor is</p></list-item></list><p><disp-formula id="equ3"> <mml:math id="m3"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">F</mml:mi></mml:mrow><mml:mrow><mml:mn>01</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msqrt><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:msup><mml:mi>s</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:msubsup><mml:mi>σ</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mfrac></mml:msqrt><mml:mspace width="thinmathspace"/><mml:mi>exp</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mo>−</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mi>θ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mfrac><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mi>θ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mi>m</mml:mi><mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mi>s</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p><code xml:space="preserve">## R function to compute Bayes factor based on effect estimate, standard
## error, null value (default is 0), prior mean (default is null value), 
## and prior standard deviation from step 1.
BF01 &lt;- function(estimate, se, null = 0, priormean = null, priorsd) {
 bf &lt;- sqrt(1 + priorsd^2/se^2)*exp(-0.5*((estimate - null)^2/se^2 -
 (estimate - priormean)^2/(se^2 + priorsd^2)))
 return(bf)
}</code></p><list list-type="order"><list-item><p>Declare replication success at level <inline-formula><mml:math id="inf87"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>γ</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>1</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> if <inline-formula><mml:math id="inf88"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>BF</mml:mi><mml:mrow><mml:mn>01</mml:mn><mml:mo>,</mml:mo><mml:mi>o</mml:mi></mml:mrow></mml:msub><mml:mo>≥</mml:mo><mml:mi>γ</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf89"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>BF</mml:mi><mml:mrow><mml:mn>01</mml:mn><mml:mo>,</mml:mo><mml:mi>r</mml:mi></mml:mrow></mml:msub><mml:mo>≥</mml:mo><mml:mi>γ</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>, conventionally <inline-formula><mml:math id="inf90"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>γ</mml:mi><mml:mo>=</mml:mo><mml:mn>3</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> (substantial evidence) or <inline-formula><mml:math id="inf91"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>γ</mml:mi><mml:mo>=</mml:mo><mml:mn>10</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> (strong evidence).</p></list-item><list-item><p>Perform a sensitivity analysis with respect to the prior distribution. For example, visualize the Bayes factors for different prior standard deviations to assess the robustness of the conclusions.</p></list-item></list></boxed-text><p>Our reanalysis of the RPCB studies with original null results showed that for most studies that meet the non-significance criterion, the conclusions are much more ambiguous – both with frequentist and Bayesian analyses. While the exact success rate depends on the equivalence margin and the prior distribution, our sensitivity analyses show that even with unrealistically liberal choices, the success rate remains below 40% which is substantially lower than the 73% success rate based on the non-significance criterion.</p><p>This is not unexpected, as a study typically requires larger sample sizes to detect the absence of an effect than to detect its presence (<xref ref-type="bibr" rid="bib45">Matthews, 2006</xref>, Section 11.5.3). Of note, the RPCB sample sizes were chosen so that each replication had at least 80% power to detect the original effect estimate based on a standard superiority test. However, the design of replication studies should ideally align with the planned analysis (<xref ref-type="bibr" rid="bib4">Anderson and Kelley, 2022</xref>) so if the goal of the study is to find evidence for the absence of an effect, the replication sample size should be determined based on a test for equivalence, see <xref ref-type="bibr" rid="bib17">Flight and Julious, 2016</xref> and <xref ref-type="bibr" rid="bib53">Pawel et al., 2023a</xref> for frequentist and Bayesian approaches, respectively.</p><p>Our reanalysis of the RPP and EPRP studies with original null results showed that Bayes factors indeed indicate some evidence for no effect in cases where the non-significance criterion was satisfied, possibly due to the smaller effects and typically larger sample sizes in these fields compared to cancer biology. On the other hand, in most cases, the precision of the effect estimates was still limited so that only one study pair achieved replication success with the equivalence testing approach. However, it is important to note that the conclusions from the RPP and EPRP analyses are merely anecdotal, as there were only four study pairs with original null results to analyze.</p><p>For both the equivalence test and the Bayes factor approach, it is critical that the equivalence margin and the prior distribution are specified independently of the data, ideally before the original and replication studies are conducted. Typically, however, the original studies were designed to find evidence for the presence of an effect, and the goal of replicating the ‘null result’ was formulated only after failure to do so. It is, therefore, important that margins and prior distributions are motivated from historical data and/or field conventions (<xref ref-type="bibr" rid="bib9">Campbell and Gustafson, 2021</xref>), and that sensitivity analyses regarding their choice are reported.</p><p>In addition, when analyzing a single pair of original and replication studies, we recommend interpreting Bayes factors and TOST <italic>p</italic>-values as quantitative measures of evidence and discourage dichotomizing them into ‘success’ or ‘failure.’ For example, two TOST <italic>p</italic>-values <inline-formula><mml:math id="inf92"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">T</mml:mi><mml:mi mathvariant="normal">O</mml:mi><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">T</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.049</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf93"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">T</mml:mi><mml:mi mathvariant="normal">O</mml:mi><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">T</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.051</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> carry similar evidential weight regardless of one being slightly smaller and the other being slightly larger than 0.05. On the other hand, when more than one pair of original and replication studies are analyzed, dichotomization may be required for computing an overall success rate. In this case, the rate may be computed for different thresholds that correspond to qualitatively different levels of evidence (e.g. 1, 3, and 10 for Bayes factors, or 0.05, 0.01, and 0.005 for <italic>p</italic>-values).</p><p>Researchers may also ask whether the equivalence test or the Bayes factor is ‘better.’ We believe that this is the wrong question to ask, because both methods address different questions and are better in different senses; the equivalence test is calibrated to have certain frequentist error rates, which the Bayes factor is not. The Bayes factor, on the other hand, seems to be a more natural measure of evidence as it treats the null and alternative hypotheses symmetrically and represents the factor by which rational agents should update their beliefs in light of the data. Replication success is ideally evaluated along multiple dimensions, as nicely exemplified by the RPCB, EPRP, and RPP. Replications that are successful on multiple criteria provide more convincing support for the original finding, while replications that are successful on fewer criteria require closer examination. Fortunately, the use of multiple methods is already standard practice in replication assessment, so our proposal to use both of them does not require a major paradigm shift.</p><p>While the equivalence test and the Bayes factor are two principled methods for analyzing original and replication studies with null results, they are not the only possible methods for doing so. A straightforward extension would be to first synthesize the original and replication effect estimates with a meta-analysis, and then apply the equivalence and Bayes factor tests to the meta-analytic estimate similar to the meta-analytic non-significance criterion used by the RPCB. This could potentially improve the power of the tests, but consideration must be given to the threshold used for the <italic>p</italic>-values/Bayes factors, as naive use of the same thresholds as in the standard approaches may make the tests too liberal (<xref ref-type="bibr" rid="bib63">Shun et al., 2005</xref>). Furthermore, there are various advanced methods for quantifying evidence for absent effects which could potentially improve on the more basic approaches considered here (<xref ref-type="bibr" rid="bib41">Lindley, 1998</xref>; <xref ref-type="bibr" rid="bib30">Johnson and Rossell, 2010</xref>; <xref ref-type="bibr" rid="bib48">Morey and Rouder, 2011</xref>; <xref ref-type="bibr" rid="bib36">Kruschke, 2018</xref>; <xref ref-type="bibr" rid="bib65">Stahel, 2021</xref>; <xref ref-type="bibr" rid="bib47">Micheloud and Held, 2023</xref>; <xref ref-type="bibr" rid="bib28">Izbicki et al., 2023</xref>).</p></sec></sec></body><back><sec sec-type="additional-information" id="s4"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Data curation, Software, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Resources, Data curation, Software, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Resources, Data curation, Formal analysis, Validation, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Resources, Supervision, Funding acquisition, Validation, Investigation, Methodology, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s5"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-92311-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s6"><title>Data availability</title><p>The code and data to reproduce our analyses is openly available at <ext-link ext-link-type="uri" xlink:href="https://gitlab.uzh.ch/samuel.pawel/rsAbsence">https://gitlab.uzh.ch/samuel.pawel/rsAbsence</ext-link>. A snapshot of the repository at the time of writing is archived at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.7906792">https://doi.org/10.5281/zenodo.7906792</ext-link> (<xref ref-type="bibr" rid="bib54">Pawel et al., 2023b</xref>). We used the statistical programming language R version 4.3.2 (<xref ref-type="bibr" rid="bib57">R Development Core Team, 2022</xref>) for analyses. The R packages ggplot2 (<xref ref-type="bibr" rid="bib68">Wickham, 2016</xref>), dplyr (<xref ref-type="bibr" rid="bib69">Wickham et al., 2022</xref>), knitr (<xref ref-type="bibr" rid="bib70">Xie, 2022</xref>), and reporttools (<xref ref-type="bibr" rid="bib59">Rufibach, 2009</xref>) were used for plotting, data preparation, dynamic reporting, and formatting, respectively. The data from the RPCB were obtained by downloading the files from <ext-link ext-link-type="uri" xlink:href="https://github.com/mayamathur/rpcb">https://github.com/mayamathur/rpcb</ext-link> (<xref ref-type="bibr" rid="bib44">Mathur, 2022</xref>; commit a1e0c63) and extracting the relevant variables as indicated in the R script preprocess-rpcb-data.R which is available in our git repository. The RPP and EPRP data were obtained from the RProjects data set available in the R package ReplicationSuccess (<xref ref-type="bibr" rid="bib26">Held, 2020</xref>), see the package documentation (<ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=ReplicationSuccess">https://CRAN.R-project.org/package=ReplicationSuccess</ext-link>) for details on data extraction.</p><p>The following previously published datasets were used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset1"><person-group person-group-type="author"><name><surname>Pawel</surname><given-names>S</given-names></name><name><surname>Held</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Data from four large-scale replication projects</data-title><source>Zenodo</source><pub-id pub-id-type="doi">10.5281/zenodo.10350448</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset2"><person-group person-group-type="author"><name><surname>Errington</surname><given-names>TM</given-names></name><name><surname>Mathur</surname><given-names>M</given-names></name><name><surname>Soderberg</surname><given-names>CK</given-names></name><name><surname>Denis</surname><given-names>A</given-names></name><name><surname>Perfito</surname><given-names>N</given-names></name><name><surname>Iorns</surname><given-names>E</given-names></name><name><surname>Nosek</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Data from the Reproducibility Project: Cancer Biology</data-title><source>Open Science Framework</source><pub-id pub-id-type="doi">10.17605/OSF.IO/SQUY7</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank the RPCB, EPRP, and RPP contributors for their tremendous efforts and for making their data publicly available. We thank Maya Mathur for her helpful advice on data preparation. We thank Benjamin Ineichen for helpful comments on drafts of the manuscript. We thank the three reviewers and the reviewing editor for useful comments that substantially improved the paper. Our acknowledgment of these individuals does not imply their endorsement of our work. We thank the Swiss National Science Foundation for financial support (grant <ext-link ext-link-type="uri" xlink:href="https://data.snf.ch/grants/grant/189295">#189295</ext-link>).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Bland</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Absence of evidence is not evidence of absence</article-title><source>BMJ</source><volume>311</volume><elocation-id>485</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.311.7003.485</pub-id><pub-id pub-id-type="pmid">7647644</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amaral</surname><given-names>OB</given-names></name><name><surname>Neves</surname><given-names>K</given-names></name><name><surname>Wasilewska-Sampaio</surname><given-names>AP</given-names></name><name><surname>Carneiro</surname><given-names>CF</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The Brazilian Reproducibility Initiative</article-title><source>eLife</source><volume>8</volume><elocation-id>e41602</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.41602</pub-id><pub-id pub-id-type="pmid">30720433</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>SF</given-names></name><name><surname>Maxwell</surname><given-names>SE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>There’s more than one way to conduct a replication study: Beyond statistical significance</article-title><source>Psychological Methods</source><volume>21</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1037/met0000051</pub-id><pub-id pub-id-type="pmid">26214497</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>SF</given-names></name><name><surname>Kelley</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Sample size planning for replication studies: The devil is in the design</article-title><source>Psychological Methods</source><volume>21</volume><elocation-id>520</elocation-id><pub-id pub-id-type="doi">10.1037/met0000520</pub-id><pub-id pub-id-type="pmid">35862114</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Begley</surname><given-names>CG</given-names></name><name><surname>Ellis</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Drug development: Raise standards for preclinical cancer research</article-title><source>Nature</source><volume>483</volume><fpage>531</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1038/483531a</pub-id><pub-id pub-id-type="pmid">22460880</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camerer</surname><given-names>CF</given-names></name><name><surname>Dreber</surname><given-names>A</given-names></name><name><surname>Forsell</surname><given-names>E</given-names></name><name><surname>Ho</surname><given-names>T-H</given-names></name><name><surname>Huber</surname><given-names>J</given-names></name><name><surname>Johannesson</surname><given-names>M</given-names></name><name><surname>Kirchler</surname><given-names>M</given-names></name><name><surname>Almenberg</surname><given-names>J</given-names></name><name><surname>Altmejd</surname><given-names>A</given-names></name><name><surname>Chan</surname><given-names>T</given-names></name><name><surname>Heikensten</surname><given-names>E</given-names></name><name><surname>Holzmeister</surname><given-names>F</given-names></name><name><surname>Imai</surname><given-names>T</given-names></name><name><surname>Isaksson</surname><given-names>S</given-names></name><name><surname>Nave</surname><given-names>G</given-names></name><name><surname>Pfeiffer</surname><given-names>T</given-names></name><name><surname>Razen</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Evaluating replicability of laboratory experiments in economics</article-title><source>Science</source><volume>351</volume><fpage>1433</fpage><lpage>1436</lpage><pub-id pub-id-type="doi">10.1126/science.aaf0918</pub-id><pub-id pub-id-type="pmid">26940865</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camerer</surname><given-names>CF</given-names></name><name><surname>Dreber</surname><given-names>A</given-names></name><name><surname>Holzmeister</surname><given-names>F</given-names></name><name><surname>Ho</surname><given-names>TH</given-names></name><name><surname>Huber</surname><given-names>J</given-names></name><name><surname>Johannesson</surname><given-names>M</given-names></name><name><surname>Kirchler</surname><given-names>M</given-names></name><name><surname>Nave</surname><given-names>G</given-names></name><name><surname>Nosek</surname><given-names>BA</given-names></name><name><surname>Pfeiffer</surname><given-names>T</given-names></name><name><surname>Altmejd</surname><given-names>A</given-names></name><name><surname>Buttrick</surname><given-names>N</given-names></name><name><surname>Chan</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Forsell</surname><given-names>E</given-names></name><name><surname>Gampa</surname><given-names>A</given-names></name><name><surname>Heikensten</surname><given-names>E</given-names></name><name><surname>Hummer</surname><given-names>L</given-names></name><name><surname>Imai</surname><given-names>T</given-names></name><name><surname>Isaksson</surname><given-names>S</given-names></name><name><surname>Manfredi</surname><given-names>D</given-names></name><name><surname>Rose</surname><given-names>J</given-names></name><name><surname>Wagenmakers</surname><given-names>EJ</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Evaluating the replicability of social science experiments in Nature and Science between 2010 and 2015</article-title><source>Nature Human Behaviour</source><volume>2</volume><fpage>637</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1038/s41562-018-0399-z</pub-id><pub-id pub-id-type="pmid">31346273</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>H</given-names></name><name><surname>Gustafson</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Conditional equivalence testing: An alternative remedy for publication bias</article-title><source>PLOS ONE</source><volume>13</volume><elocation-id>e0195145</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0195145</pub-id><pub-id pub-id-type="pmid">29652891</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>H</given-names></name><name><surname>Gustafson</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>What to make of equivalence testing with a post-specified margin?</article-title><source>Meta-Psychology</source><volume>5</volume><elocation-id>2506</elocation-id><pub-id pub-id-type="doi">10.15626/MP.2020.2506</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>A power primer</article-title><source>Psychological Bulletin</source><volume>112</volume><fpage>155</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1037//0033-2909.112.1.155</pub-id><pub-id pub-id-type="pmid">19565683</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>H</given-names></name><name><surname>Hedges</surname><given-names>LV</given-names></name><name><surname>Valentine</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2019">2019</year><source>The Handbook of Research Synthesis and Meta-Analysis</source><publisher-name>Russell Sage Foundation</publisher-name><pub-id pub-id-type="doi">10.7758/9781610448864</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cova</surname><given-names>F</given-names></name><name><surname>Strickland</surname><given-names>B</given-names></name><name><surname>Abatista</surname><given-names>A</given-names></name><name><surname>Allard</surname><given-names>A</given-names></name><name><surname>Andow</surname><given-names>J</given-names></name><name><surname>Attie</surname><given-names>M</given-names></name><name><surname>Beebe</surname><given-names>J</given-names></name><name><surname>Berniūnas</surname><given-names>R</given-names></name><name><surname>Boudesseul</surname><given-names>J</given-names></name><name><surname>Colombo</surname><given-names>M</given-names></name><name><surname>Cushman</surname><given-names>F</given-names></name><name><surname>Diaz</surname><given-names>R</given-names></name><name><surname>N’Djaye Nikolai van Dongen</surname><given-names>N</given-names></name><name><surname>Dranseika</surname><given-names>V</given-names></name><name><surname>Earp</surname><given-names>BD</given-names></name><name><surname>Torres</surname><given-names>AG</given-names></name><name><surname>Hannikainen</surname><given-names>I</given-names></name><name><surname>Hernández-Conde</surname><given-names>JV</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Jaquet</surname><given-names>F</given-names></name><name><surname>Khalifa</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Kneer</surname><given-names>M</given-names></name><name><surname>Knobe</surname><given-names>J</given-names></name><name><surname>Kurthy</surname><given-names>M</given-names></name><name><surname>Lantian</surname><given-names>A</given-names></name><name><surname>Liao</surname><given-names>S</given-names></name><name><surname>Machery</surname><given-names>E</given-names></name><name><surname>Moerenhout</surname><given-names>T</given-names></name><name><surname>Mott</surname><given-names>C</given-names></name><name><surname>Phelan</surname><given-names>M</given-names></name><name><surname>Phillips</surname><given-names>J</given-names></name><name><surname>Rambharose</surname><given-names>N</given-names></name><name><surname>Reuter</surname><given-names>K</given-names></name><name><surname>Romero</surname><given-names>F</given-names></name><name><surname>Sousa</surname><given-names>P</given-names></name><name><surname>Sprenger</surname><given-names>J</given-names></name><name><surname>Thalabard</surname><given-names>E</given-names></name><name><surname>Tobia</surname><given-names>K</given-names></name><name><surname>Viciana</surname><given-names>H</given-names></name><name><surname>Wilkenfeld</surname><given-names>D</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Estimating the reproducibility of experimental philosophy</article-title><source>Review of Philosophy and Psychology</source><volume>12</volume><fpage>9</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1007/s13164-018-0400-9</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson</surname><given-names>MA</given-names></name><name><surname>Prinjha</surname><given-names>RK</given-names></name><name><surname>Dittmann</surname><given-names>A</given-names></name><name><surname>Giotopoulos</surname><given-names>G</given-names></name><name><surname>Bantscheff</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>WI</given-names></name><name><surname>Robson</surname><given-names>SC</given-names></name><name><surname>Chung</surname><given-names>C</given-names></name><name><surname>Hopf</surname><given-names>C</given-names></name><name><surname>Savitski</surname><given-names>MM</given-names></name><name><surname>Huthmacher</surname><given-names>C</given-names></name><name><surname>Gudgin</surname><given-names>E</given-names></name><name><surname>Lugo</surname><given-names>D</given-names></name><name><surname>Beinke</surname><given-names>S</given-names></name><name><surname>Chapman</surname><given-names>TD</given-names></name><name><surname>Roberts</surname><given-names>EJ</given-names></name><name><surname>Soden</surname><given-names>PE</given-names></name><name><surname>Auger</surname><given-names>KR</given-names></name><name><surname>Mirguet</surname><given-names>O</given-names></name><name><surname>Doehner</surname><given-names>K</given-names></name><name><surname>Delwel</surname><given-names>R</given-names></name><name><surname>Burnett</surname><given-names>AK</given-names></name><name><surname>Jeffrey</surname><given-names>P</given-names></name><name><surname>Drewes</surname><given-names>G</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Huntly</surname><given-names>BJP</given-names></name><name><surname>Kouzarides</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia</article-title><source>Nature</source><volume>478</volume><fpage>529</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1038/nature10509</pub-id><pub-id pub-id-type="pmid">21964340</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dienes</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Using Bayes to get the most out of non-significant results</article-title><source>Frontiers in Psychology</source><volume>5</volume><elocation-id>781</elocation-id><pub-id pub-id-type="doi">10.3389/fpsyg.2014.00781</pub-id><pub-id pub-id-type="pmid">25120503</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eastwick</surname><given-names>PW</given-names></name><name><surname>Finkel</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Sex differences in mate preferences revisited: do people know what they initially desire in a romantic partner?</article-title><source>Journal of Personality and Social Psychology</source><volume>94</volume><fpage>245</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1037/0022-3514.94.2.245</pub-id><pub-id pub-id-type="pmid">18211175</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Errington</surname><given-names>TM</given-names></name><name><surname>Mathur</surname><given-names>M</given-names></name><name><surname>Soderberg</surname><given-names>CK</given-names></name><name><surname>Denis</surname><given-names>A</given-names></name><name><surname>Perfito</surname><given-names>N</given-names></name><name><surname>Iorns</surname><given-names>E</given-names></name><name><surname>Nosek</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Investigating the replicability of preclinical cancer biology</article-title><source>eLife</source><volume>10</volume><elocation-id>e71601</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.71601</pub-id><pub-id pub-id-type="pmid">34874005</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flight</surname><given-names>L</given-names></name><name><surname>Julious</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Practical guide to sample size calculations: non-inferiority and equivalence trials</article-title><source>Pharmaceutical Statistics</source><volume>15</volume><fpage>80</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1002/pst.1716</pub-id><pub-id pub-id-type="pmid">26604186</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goetz</surname><given-names>JG</given-names></name><name><surname>Minguet</surname><given-names>S</given-names></name><name><surname>Navarro-Lérida</surname><given-names>I</given-names></name><name><surname>Lazcano</surname><given-names>JJ</given-names></name><name><surname>Samaniego</surname><given-names>R</given-names></name><name><surname>Calvo</surname><given-names>E</given-names></name><name><surname>Tello</surname><given-names>M</given-names></name><name><surname>Osteso-Ibáñez</surname><given-names>T</given-names></name><name><surname>Pellinen</surname><given-names>T</given-names></name><name><surname>Echarri</surname><given-names>A</given-names></name><name><surname>Cerezo</surname><given-names>A</given-names></name><name><surname>Klein-Szanto</surname><given-names>AJP</given-names></name><name><surname>Garcia</surname><given-names>R</given-names></name><name><surname>Keely</surname><given-names>PJ</given-names></name><name><surname>Sánchez-Mateos</surname><given-names>P</given-names></name><name><surname>Cukierman</surname><given-names>E</given-names></name><name><surname>Del Pozo</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis</article-title><source>Cell</source><volume>146</volume><fpage>148</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.05.040</pub-id><pub-id pub-id-type="pmid">21729786</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodman</surname><given-names>SN</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Toward evidence-based medical statistics. 2: The Bayes factor</article-title><source>Annals of Internal Medicine</source><volume>130</volume><fpage>1005</fpage><lpage>1013</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-130-12-199906150-00019</pub-id><pub-id pub-id-type="pmid">10383350</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodman</surname><given-names>SN</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Introduction to Bayesian methods I: measuring the strength of evidence</article-title><source>Clinical Trials</source><volume>2</volume><fpage>282</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1191/1740774505cn098oa</pub-id><pub-id pub-id-type="pmid">16281426</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenland</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Null misinterpretation in statistical testing and its impact on health risk assessment</article-title><source>Preventive Medicine</source><volume>53</volume><fpage>225</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/j.ypmed.2011.08.010</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenland</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Nonsignificance plus high power does not imply support for the null over the alternative</article-title><source>Annals of Epidemiology</source><volume>22</volume><fpage>364</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1016/j.annepidem.2012.02.007</pub-id><pub-id pub-id-type="pmid">22391267</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenland</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Divergence versus decision <italic>P</italic>-values: a distinction worth making in theory and keeping in practice: or, how divergence <italic>P</italic>-values measure evidence even when decision <italic>P</italic>-values do not</article-title><source>Scandinavian Journal of Statistics</source><volume>50</volume><fpage>54</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1111/sjos.12625</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauck</surname><given-names>WW</given-names></name><name><surname>Anderson</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>A proposal for interpreting and reporting negative studies</article-title><source>Statistics in Medicine</source><volume>5</volume><fpage>203</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1002/sim.4780050302</pub-id><pub-id pub-id-type="pmid">3526499</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Held</surname><given-names>L</given-names></name><name><surname>Ott</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>On <italic>p</italic>-values and Bayes factors</article-title><source>Annual Review of Statistics and Its Application</source><volume>5</volume><fpage>393</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1146/annurev-statistics-031017-100307</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Held</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A new standard for the analysis and design of replication studies</article-title><source>Journal of the Royal Statistical Society Series A</source><volume>183</volume><fpage>431</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1111/rssa.12493</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoenig</surname><given-names>JM</given-names></name><name><surname>Heisey</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>The abuse of power</article-title><source>The American Statistician</source><volume>55</volume><fpage>19</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1198/000313001300339897</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Izbicki</surname><given-names>R</given-names></name><name><surname>Cabezas</surname><given-names>LMC</given-names></name><name><surname>Colugnatti</surname><given-names>FAB</given-names></name><name><surname>Lassance</surname><given-names>RFL</given-names></name><name><surname>de</surname><given-names>AAL</given-names></name><name><surname>Stern</surname><given-names>RB</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Rethinking Hypothesis Tests</article-title><source>arXiv</source><ext-link ext-link-type="uri" xlink:href="https://arxiv.org/abs/2308.09112">https://arxiv.org/abs/2308.09112</ext-link></element-citation></ref><ref id="bib29"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jeffreys</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1961">1961</year><source>Theory of Probability</source><publisher-name>Clarendon Press</publisher-name></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>VE</given-names></name><name><surname>Rossell</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>On the use of non-local prior densities in Bayesian hypothesis tests</article-title><source>Journal of the Royal Statistical Society Series B</source><volume>72</volume><fpage>143</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1111/j.1467-9868.2009.00730.x</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kass</surname><given-names>RE</given-names></name><name><surname>Raftery</surname><given-names>AE</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Bayes factors</article-title><source>Journal of the American Statistical Association</source><volume>90</volume><fpage>773</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1080/01621459.1995.10476572</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kass</surname><given-names>RE</given-names></name><name><surname>Wasserman</surname><given-names>L</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>A reference Bayesian test for nested hypotheses and its relationship to the Schwarz criterion</article-title><source>Journal of the American Statistical Association</source><volume>90</volume><fpage>928</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1080/01621459.1995.10476592</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keysers</surname><given-names>C</given-names></name><name><surname>Gazzola</surname><given-names>V</given-names></name><name><surname>Wagenmakers</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Using Bayes factor hypothesis testing in neuroscience to establish evidence of absence</article-title><source>Nature Neuroscience</source><volume>23</volume><fpage>788</fpage><lpage>799</lpage><pub-id pub-id-type="doi">10.1038/s41593-020-0660-4</pub-id><pub-id pub-id-type="pmid">32601411</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>RA</given-names></name><name><surname>Ratliff</surname><given-names>KA</given-names></name><name><surname>Vianello</surname><given-names>M</given-names></name><name><surname>Adams</surname><given-names>RB</given-names></name><name><surname>Bahník</surname><given-names>V</given-names></name><name><surname>Bernstein</surname><given-names>MJ</given-names></name><name><surname>Bocian</surname><given-names>K</given-names></name><name><surname>Brandt</surname><given-names>MJ</given-names></name><name><surname>Brooks</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Investigating variation in replicability: A “many labs” replication project</article-title><source>Social Psychology</source><volume>45</volume><fpage>142</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1027/1864-9335/a000178</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>RA</given-names></name><name><surname>Vianello</surname><given-names>M</given-names></name><name><surname>Hasselman</surname><given-names>F</given-names></name><name><surname>Adams</surname><given-names>BG</given-names></name><name><surname>Adams</surname><given-names>RB</given-names></name><name><surname>Alper</surname><given-names>S</given-names></name><name><surname>Aveyard</surname><given-names>M</given-names></name><name><surname>Axt</surname><given-names>JR</given-names></name><name><surname>Babalola</surname><given-names>MT</given-names></name><name><surname>Bahník</surname><given-names>Š</given-names></name><name><surname>Batra</surname><given-names>R</given-names></name><name><surname>Berkics</surname><given-names>M</given-names></name><name><surname>Bernstein</surname><given-names>MJ</given-names></name><name><surname>Berry</surname><given-names>DR</given-names></name><name><surname>Bialobrzeska</surname><given-names>O</given-names></name><name><surname>Binan</surname><given-names>ED</given-names></name><name><surname>Bocian</surname><given-names>K</given-names></name><name><surname>Brandt</surname><given-names>MJ</given-names></name><name><surname>Busching</surname><given-names>R</given-names></name><name><surname>Rédei</surname><given-names>AC</given-names></name><name><surname>Cai</surname><given-names>H</given-names></name><name><surname>Cambier</surname><given-names>F</given-names></name><name><surname>Cantarero</surname><given-names>K</given-names></name><name><surname>Carmichael</surname><given-names>CL</given-names></name><name><surname>Ceric</surname><given-names>F</given-names></name><name><surname>Chandler</surname><given-names>J</given-names></name><name><surname>Chang</surname><given-names>J-H</given-names></name><name><surname>Chatard</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>EE</given-names></name><name><surname>Cheong</surname><given-names>W</given-names></name><name><surname>Cicero</surname><given-names>DC</given-names></name><name><surname>Coen</surname><given-names>S</given-names></name><name><surname>Coleman</surname><given-names>JA</given-names></name><name><surname>Collisson</surname><given-names>B</given-names></name><name><surname>Conway</surname><given-names>MA</given-names></name><name><surname>Corker</surname><given-names>KS</given-names></name><name><surname>Curran</surname><given-names>PG</given-names></name><name><surname>Cushman</surname><given-names>F</given-names></name><name><surname>Dagona</surname><given-names>ZK</given-names></name><name><surname>Dalgar</surname><given-names>I</given-names></name><name><surname>Dalla Rosa</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>WE</given-names></name><name><surname>de Bruijn</surname><given-names>M</given-names></name><name><surname>De Schutter</surname><given-names>L</given-names></name><name><surname>Devos</surname><given-names>T</given-names></name><name><surname>de Vries</surname><given-names>M</given-names></name><name><surname>Doğulu</surname><given-names>C</given-names></name><name><surname>Dozo</surname><given-names>N</given-names></name><name><surname>Dukes</surname><given-names>KN</given-names></name><name><surname>Dunham</surname><given-names>Y</given-names></name><name><surname>Durrheim</surname><given-names>K</given-names></name><name><surname>Ebersole</surname><given-names>CR</given-names></name><name><surname>Edlund</surname><given-names>JE</given-names></name><name><surname>Eller</surname><given-names>A</given-names></name><name><surname>English</surname><given-names>AS</given-names></name><name><surname>Finck</surname><given-names>C</given-names></name><name><surname>Frankowska</surname><given-names>N</given-names></name><name><surname>Freyre</surname><given-names>M-Á</given-names></name><name><surname>Friedman</surname><given-names>M</given-names></name><name><surname>Galliani</surname><given-names>EM</given-names></name><name><surname>Gandi</surname><given-names>JC</given-names></name><name><surname>Ghoshal</surname><given-names>T</given-names></name><name><surname>Giessner</surname><given-names>SR</given-names></name><name><surname>Gill</surname><given-names>T</given-names></name><name><surname>Gnambs</surname><given-names>T</given-names></name><name><surname>Gómez</surname><given-names>Á</given-names></name><name><surname>González</surname><given-names>R</given-names></name><name><surname>Graham</surname><given-names>J</given-names></name><name><surname>Grahe</surname><given-names>JE</given-names></name><name><surname>Grahek</surname><given-names>I</given-names></name><name><surname>Green</surname><given-names>EGT</given-names></name><name><surname>Hai</surname><given-names>K</given-names></name><name><surname>Haigh</surname><given-names>M</given-names></name><name><surname>Haines</surname><given-names>EL</given-names></name><name><surname>Hall</surname><given-names>MP</given-names></name><name><surname>Heffernan</surname><given-names>ME</given-names></name><name><surname>Hicks</surname><given-names>JA</given-names></name><name><surname>Houdek</surname><given-names>P</given-names></name><name><surname>Huntsinger</surname><given-names>JR</given-names></name><name><surname>Huynh</surname><given-names>HP</given-names></name><name><surname>IJzerman</surname><given-names>H</given-names></name><name><surname>Inbar</surname><given-names>Y</given-names></name><name><surname>Innes-Ker</surname><given-names>ÅH</given-names></name><name><surname>Jiménez-Leal</surname><given-names>W</given-names></name><name><surname>John</surname><given-names>M-S</given-names></name><name><surname>Joy-Gaba</surname><given-names>JA</given-names></name><name><surname>Kamiloğlu</surname><given-names>RG</given-names></name><name><surname>Kappes</surname><given-names>HB</given-names></name><name><surname>Karabati</surname><given-names>S</given-names></name><name><surname>Karick</surname><given-names>H</given-names></name><name><surname>Keller</surname><given-names>VN</given-names></name><name><surname>Kende</surname><given-names>A</given-names></name><name><surname>Kervyn</surname><given-names>N</given-names></name><name><surname>Knežević</surname><given-names>G</given-names></name><name><surname>Kovacs</surname><given-names>C</given-names></name><name><surname>Krueger</surname><given-names>LE</given-names></name><name><surname>Kurapov</surname><given-names>G</given-names></name><name><surname>Kurtz</surname><given-names>J</given-names></name><name><surname>Lakens</surname><given-names>D</given-names></name><name><surname>Lazarević</surname><given-names>LB</given-names></name><name><surname>Levitan</surname><given-names>CA</given-names></name><name><surname>Lewis</surname><given-names>NA</given-names></name><name><surname>Lins</surname><given-names>S</given-names></name><name><surname>Lipsey</surname><given-names>NP</given-names></name><name><surname>Losee</surname><given-names>JE</given-names></name><name><surname>Maassen</surname><given-names>E</given-names></name><name><surname>Maitner</surname><given-names>AT</given-names></name><name><surname>Malingumu</surname><given-names>W</given-names></name><name><surname>Mallett</surname><given-names>RK</given-names></name><name><surname>Marotta</surname><given-names>SA</given-names></name><name><surname>Međedović</surname><given-names>J</given-names></name><name><surname>Mena-Pacheco</surname><given-names>F</given-names></name><name><surname>Milfont</surname><given-names>TL</given-names></name><name><surname>Morris</surname><given-names>WL</given-names></name><name><surname>Murphy</surname><given-names>SC</given-names></name><name><surname>Myachykov</surname><given-names>A</given-names></name><name><surname>Neave</surname><given-names>N</given-names></name><name><surname>Neijenhuijs</surname><given-names>K</given-names></name><name><surname>Nelson</surname><given-names>AJ</given-names></name><name><surname>Neto</surname><given-names>F</given-names></name><name><surname>Lee Nichols</surname><given-names>A</given-names></name><name><surname>Ocampo</surname><given-names>A</given-names></name><name><surname>O’Donnell</surname><given-names>SL</given-names></name><name><surname>Oikawa</surname><given-names>H</given-names></name><name><surname>Oikawa</surname><given-names>M</given-names></name><name><surname>Ong</surname><given-names>E</given-names></name><name><surname>Orosz</surname><given-names>G</given-names></name><name><surname>Osowiecka</surname><given-names>M</given-names></name><name><surname>Packard</surname><given-names>G</given-names></name><name><surname>Pérez-Sánchez</surname><given-names>R</given-names></name><name><surname>Petrović</surname><given-names>B</given-names></name><name><surname>Pilati</surname><given-names>R</given-names></name><name><surname>Pinter</surname><given-names>B</given-names></name><name><surname>Podesta</surname><given-names>L</given-names></name><name><surname>Pogge</surname><given-names>G</given-names></name><name><surname>Pollmann</surname><given-names>MMH</given-names></name><name><surname>Rutchick</surname><given-names>AM</given-names></name><name><surname>Saavedra</surname><given-names>P</given-names></name><name><surname>Saeri</surname><given-names>AK</given-names></name><name><surname>Salomon</surname><given-names>E</given-names></name><name><surname>Schmidt</surname><given-names>K</given-names></name><name><surname>Schönbrodt</surname><given-names>FD</given-names></name><name><surname>Sekerdej</surname><given-names>MB</given-names></name><name><surname>Sirlopú</surname><given-names>D</given-names></name><name><surname>Skorinko</surname><given-names>JLM</given-names></name><name><surname>Smith</surname><given-names>MA</given-names></name><name><surname>Smith-Castro</surname><given-names>V</given-names></name><name><surname>Smolders</surname><given-names>KCHJ</given-names></name><name><surname>Sobkow</surname><given-names>A</given-names></name><name><surname>Sowden</surname><given-names>W</given-names></name><name><surname>Spachtholz</surname><given-names>P</given-names></name><name><surname>Srivastava</surname><given-names>M</given-names></name><name><surname>Steiner</surname><given-names>TG</given-names></name><name><surname>Stouten</surname><given-names>J</given-names></name><name><surname>Street</surname><given-names>CNH</given-names></name><name><surname>Sundfelt</surname><given-names>OK</given-names></name><name><surname>Szeto</surname><given-names>S</given-names></name><name><surname>Szumowska</surname><given-names>E</given-names></name><name><surname>Tang</surname><given-names>ACW</given-names></name><name><surname>Tanzer</surname><given-names>N</given-names></name><name><surname>Tear</surname><given-names>MJ</given-names></name><name><surname>Theriault</surname><given-names>J</given-names></name><name><surname>Thomae</surname><given-names>M</given-names></name><name><surname>Torres</surname><given-names>D</given-names></name><name><surname>Traczyk</surname><given-names>J</given-names></name><name><surname>Tybur</surname><given-names>JM</given-names></name><name><surname>Ujhelyi</surname><given-names>A</given-names></name><name><surname>van Aert</surname><given-names>RCM</given-names></name><name><surname>van Assen</surname><given-names>MALM</given-names></name><name><surname>van der Hulst</surname><given-names>M</given-names></name><name><surname>van Lange</surname><given-names>PAM</given-names></name><name><surname>van ’t Veer</surname><given-names>AE</given-names></name><name><surname>Vásquez- Echeverría</surname><given-names>A</given-names></name><name><surname>Ann Vaughn</surname><given-names>L</given-names></name><name><surname>Vázquez</surname><given-names>A</given-names></name><name><surname>Vega</surname><given-names>LD</given-names></name><name><surname>Verniers</surname><given-names>C</given-names></name><name><surname>Verschoor</surname><given-names>M</given-names></name><name><surname>Voermans</surname><given-names>IPJ</given-names></name><name><surname>Vranka</surname><given-names>MA</given-names></name><name><surname>Welch</surname><given-names>C</given-names></name><name><surname>Wichman</surname><given-names>AL</given-names></name><name><surname>Williams</surname><given-names>LA</given-names></name><name><surname>Wood</surname><given-names>M</given-names></name><name><surname>Woodzicka</surname><given-names>JA</given-names></name><name><surname>Wronska</surname><given-names>MK</given-names></name><name><surname>Young</surname><given-names>L</given-names></name><name><surname>Zelenski</surname><given-names>JM</given-names></name><name><surname>Zhijia</surname><given-names>Z</given-names></name><name><surname>Nosek</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Many labs 2: investigating variation in replicability across samples and settings</article-title><source>Advances in Methods and Practices in Psychological Science</source><volume>1</volume><fpage>443</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1177/2515245918810225</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kruschke</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Rejecting or accepting parameter values in Bayesian estimation</article-title><source>Advances in Methods and Practices in Psychological Science</source><volume>1</volume><fpage>270</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1177/2515245918771304</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lakens</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Equivalence tests</article-title><source>Social Psychological and Personality Science</source><volume>8</volume><fpage>355</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1177/1948550617697177</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lange</surname><given-names>S</given-names></name><name><surname>Freitag</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Choice of delta: requirements and reality – results of a systematic review</article-title><source>Biometrical Journal. Biometrische Zeitschrift</source><volume>47</volume><fpage>12</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1002/bimj.200410085</pub-id><pub-id pub-id-type="pmid">16395993</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>LM</given-names></name><name><surname>Edwards</surname><given-names>MC</given-names></name><name><surname>Meyers</surname><given-names>ZR</given-names></name><name><surname>Talbot</surname><given-names>CC</given-names></name><name><surname>Hao</surname><given-names>H</given-names></name><name><surname>Blum</surname><given-names>D</given-names></name><name><surname>Iorns</surname><given-names>E</given-names></name><name><surname>Tsui</surname><given-names>R</given-names></name><name><surname>Denis</surname><given-names>A</given-names></name><name><surname>Perfito</surname><given-names>N</given-names></name><name><surname>Errington</surname><given-names>TM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Replication study: transcriptional amplification in tumor cells with elevated c-Myc</article-title><source>eLife</source><volume>7</volume><elocation-id>e30274</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.30274</pub-id><pub-id pub-id-type="pmid">29313490</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>CY</given-names></name><name><surname>Lovén</surname><given-names>J</given-names></name><name><surname>Rahl</surname><given-names>PB</given-names></name><name><surname>Paranal</surname><given-names>RM</given-names></name><name><surname>Burge</surname><given-names>CB</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name><name><surname>Lee</surname><given-names>TI</given-names></name><name><surname>Young</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Transcriptional amplification in tumor cells with elevated c-Myc</article-title><source>Cell</source><volume>151</volume><fpage>56</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.08.026</pub-id><pub-id pub-id-type="pmid">23021215</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindley</surname><given-names>DV</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Decision analysis and bioequivalence trials</article-title><source>Statistical Science</source><volume>13</volume><elocation-id>1028905932</elocation-id><pub-id pub-id-type="doi">10.1214/ss/1028905932</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makin</surname><given-names>TR</given-names></name><name><surname>Orban de Xivry</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Ten common statistical mistakes to watch out for when writing or reviewing a manuscript</article-title><source>eLife</source><volume>8</volume><elocation-id>e48175</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.48175</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathur</surname><given-names>MB</given-names></name><name><surname>VanderWeele</surname><given-names>TJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>New statistical metrics for multisite replication projects</article-title><source>Journal of the Royal Statistical Society Series A</source><volume>183</volume><fpage>1145</fpage><lpage>1166</lpage><pub-id pub-id-type="doi">10.1111/rssa.12572</pub-id><pub-id pub-id-type="pmid">33132447</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Mathur</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Rpcb</data-title><version designator="a1e0c63">a1e0c63</version><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/mayamathur/rpcb">https://github.com/mayamathur/rpcb</ext-link></element-citation></ref><ref id="bib45"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>JNS</given-names></name></person-group><year iso-8601-date="2006">2006</year><source>Introduction to Randomized Controlled Clinical Trials</source><publisher-name>Chapman and Hall/CRC</publisher-name><pub-id pub-id-type="doi">10.1201/9781420011302</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCann</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Intentional action and intending: recent empirical studies</article-title><source>Philosophical Psychology</source><volume>18</volume><fpage>737</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1080/09515080500355236</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Micheloud</surname><given-names>C</given-names></name><name><surname>Held</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The replication of equivalence studies</article-title><source>arXiv</source><pub-id pub-id-type="doi">10.48550/ARXIV.2204.06960</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morey</surname><given-names>RD</given-names></name><name><surname>Rouder</surname><given-names>JN</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Bayes factor approaches for testing interval null hypotheses</article-title><source>Psychological Methods</source><volume>16</volume><fpage>406</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1037/a0024377</pub-id><pub-id pub-id-type="pmid">21787084</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>J</given-names></name><name><surname>Mesquida</surname><given-names>C</given-names></name><name><surname>Caldwell</surname><given-names>AR</given-names></name><name><surname>Earp</surname><given-names>BD</given-names></name><name><surname>Warne</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Proposal of a selection potocol for replication of studies in sports and exercise science</article-title><source>Sports Medicine</source><volume>53</volume><fpage>281</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1007/s40279-022-01749-1</pub-id><pub-id pub-id-type="pmid">36066754</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="book"><person-group person-group-type="author"><collab>National Academies of Sciences, Engineering, and Medicine</collab></person-group><year iso-8601-date="2019">2019</year><source>Reproducibility and Replicability in Science</source><publisher-name>National Academies Press</publisher-name></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Open Science Collaboration</collab></person-group><year iso-8601-date="2015">2015</year><article-title>Estimating the reproducibility of psychological science</article-title><source>Science</source><volume>349</volume><elocation-id>eaac4716</elocation-id><pub-id pub-id-type="doi">10.1126/science.aac4716</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patil</surname><given-names>P</given-names></name><name><surname>Peng</surname><given-names>RD</given-names></name><name><surname>Leek</surname><given-names>JT</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>What should researchers expect when they replicate studies? a statistical view of replicability in psychological science</article-title><source>Perspectives on Psychological Science</source><volume>11</volume><fpage>539</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1177/1745691616646366</pub-id><pub-id pub-id-type="pmid">27474140</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawel</surname><given-names>S</given-names></name><name><surname>Consonni</surname><given-names>G</given-names></name><name><surname>Held</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2023">2023a</year><article-title>Bayesian approaches to designing replication studies</article-title><source>Psychological Methods</source><volume>1</volume><elocation-id>604</elocation-id><pub-id pub-id-type="doi">10.1037/met0000604</pub-id><pub-id pub-id-type="pmid">37561490</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Pawel</surname><given-names>S</given-names></name><name><surname>Heyard</surname><given-names>R</given-names></name><name><surname>Micheloud</surname><given-names>C</given-names></name><name><surname>Held</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2023">2023b</year><data-title>Replication of &quot;null results&quot; - absence of evidence or evidence of absence?</data-title><source>Zenodo</source><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.7906792">https://doi.org/10.5281/zenodo.7906792</ext-link></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prinz</surname><given-names>F</given-names></name><name><surname>Schlange</surname><given-names>T</given-names></name><name><surname>Asadullah</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Believe it or not: how much can we rely on published data on potential drug targets?</article-title><source>Nature Reviews. Drug Discovery</source><volume>10</volume><elocation-id>712</elocation-id><pub-id pub-id-type="doi">10.1038/nrd3439-c1</pub-id><pub-id pub-id-type="pmid">21892149</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranganath</surname><given-names>KA</given-names></name><name><surname>Nosek</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Implicit attitude generalization occurs immediately; explicit attitude generalization takes time</article-title><source>Psychological Science</source><volume>19</volume><fpage>249</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1111/j.1467-9280.2008.02076.x</pub-id><pub-id pub-id-type="pmid">18315797</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="software"><person-group person-group-type="author"><collab>R Development Core Team</collab></person-group><year iso-8601-date="2022">2022</year><data-title>R: A Language and Environment for Statistical Computing</data-title><publisher-loc>Vienna, Austria</publisher-loc><publisher-name>R Foundation for Statistical Computing</publisher-name><ext-link ext-link-type="uri" xlink:href="https://www.R-project.org">https://www.R-project.org</ext-link></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reynolds</surname><given-names>M</given-names></name><name><surname>Besner</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Contextual effects on reading aloud: evidence for pathway control</article-title><source>Journal of Experimental Psychology. Learning, Memory, and Cognition</source><volume>34</volume><fpage>50</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1037/0278-7393.34.1.50</pub-id><pub-id pub-id-type="pmid">18194054</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rufibach</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>reporttools: R functions to generate LaTeX tables of descriptive statistics</article-title><source>Journal of Statistical Software, Code Snippets</source><volume>31</volume><elocation-id>v031</elocation-id><pub-id pub-id-type="doi">10.18637/jss.v031.c01</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schauer</surname><given-names>JM</given-names></name><name><surname>Hedges</surname><given-names>LV</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Reconsidering statistical methods for assessing replication</article-title><source>Psychological Methods</source><volume>26</volume><fpage>127</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1037/met0000302</pub-id><pub-id pub-id-type="pmid">33617275</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuirmann</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability</article-title><source>Journal of Pharmacokinetics and Biopharmaceutics</source><volume>15</volume><fpage>657</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1007/BF01068419</pub-id><pub-id pub-id-type="pmid">3450848</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Senn</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><source>Statistical Issues in Drug Development</source><publisher-name>Wiley</publisher-name><pub-id pub-id-type="doi">10.1002/9781119238614</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shun</surname><given-names>Z</given-names></name><name><surname>Chi</surname><given-names>E</given-names></name><name><surname>Durrleman</surname><given-names>S</given-names></name><name><surname>Fisher</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Statistical consideration of the strategy for demonstrating clinical evidence of effectiveness—one larger vs two smaller pivotal studies</article-title><source>Statistics in Medicine</source><volume>24</volume><fpage>1619</fpage><lpage>1637</lpage><pub-id pub-id-type="doi">10.1002/sim.2015</pub-id><pub-id pub-id-type="pmid">15568207</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Spiegelhalter</surname><given-names>DJ</given-names></name><name><surname>Abrams</surname><given-names>KR</given-names></name><name><surname>Myles</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2003">2003</year><source>Bayesian Approaches to Clinical Trials and Health-Care Evaluation</source><publisher-name>Wiley</publisher-name><pub-id pub-id-type="doi">10.1002/0470092602</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stahel</surname><given-names>WA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>New relevance and significance measures to replace p-values</article-title><source>PLOS ONE</source><volume>16</volume><elocation-id>e0252991</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0252991</pub-id><pub-id pub-id-type="pmid">34133444</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wellek</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><source>Testing Statistical Hypotheses of Equivalence and Noninferiority</source><publisher-name>CRC press</publisher-name><pub-id pub-id-type="doi">10.1201/EBK1439808184</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westlake</surname><given-names>WJ</given-names></name></person-group><year iso-8601-date="1972">1972</year><article-title>Use of confidence intervals in analysis of comparative bioavailability trials</article-title><source>Journal of Pharmaceutical Sciences</source><volume>61</volume><fpage>1340</fpage><lpage>1341</lpage><pub-id pub-id-type="doi">10.1002/jps.2600610845</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wickham</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><source>ggplot2: Elegant Graphics for Data Analysis</source><publisher-name>Springer International Publishing</publisher-name><pub-id pub-id-type="doi">10.1007/978-3-319-24277-4</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Wickham</surname><given-names>H</given-names></name><name><surname>François</surname><given-names>R</given-names></name><name><surname>Henry</surname><given-names>L</given-names></name><name><surname>Müller</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>dplyr: A Grammar of Data Manipulation</data-title><source>R package Version 1.0.10</source><ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=dplyr">https://CRAN.R-project.org/package=dplyr</ext-link></element-citation></ref><ref id="bib70"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>knitr: A general-purpose package for dynamic report generation in R</data-title><source>R Package Version 1.40</source><ext-link ext-link-type="uri" xlink:href="https://yihui.org/knitr">https://yihui.org/knitr</ext-link></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><sec sec-type="appendix" id="s7"><title>Sensitivity analyses</title><p>The post-hoc specification of equivalence margins <inline-formula><mml:math id="inf94"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi mathvariant="normal">Δ</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> and prior distribution for the SMD under the alternative <inline-formula><mml:math id="inf95"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> is debatable. Commonly used margins in clinical research are much more stringent (<xref ref-type="bibr" rid="bib38">Lange and Freitag, 2005</xref>); for instance, in oncology, a margin of <inline-formula><mml:math id="inf96"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi mathvariant="normal">Δ</mml:mi><mml:mo>=</mml:mo><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1.3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> is commonly used for log odds/hazard ratios, whereas in bioequivalence studies a margin of <inline-formula><mml:math id="inf97"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi mathvariant="normal">Δ</mml:mi><mml:mo>=</mml:mo><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1.25</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> is the convention (<xref ref-type="bibr" rid="bib62">Senn, 2021</xref>, Chapter 22). These margins would translate into margins of <inline-formula><mml:math id="inf98"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi mathvariant="normal">Δ</mml:mi><mml:mo>=</mml:mo><mml:mn>0.14</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf99"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi mathvariant="normal">Δ</mml:mi><mml:mo>=</mml:mo><mml:mn>0.12</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> on the SMD scale, respectively, using the <inline-formula><mml:math id="inf100"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mtext>SMD</mml:mtext><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mo stretchy="false">√</mml:mo><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>π</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:mtext>OR</mml:mtext></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> conversion (<xref ref-type="bibr" rid="bib11">Cooper et al., 2019</xref>, p. 233). Similarly, for the Bayes factor we specified a normal unit-information prior under the alternative while other normal priors with smaller/larger standard deviations could have been considered. Here, we therefore investigate the sensitivity of our conclusions with respect to these parameters.</p><p>The top plot of <xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1</xref> shows the number of successful replications as a function of the margin <inline-formula><mml:math id="inf101"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi mathvariant="normal">Δ</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> and for different TOST <italic>p</italic>-value thresholds. Such an ‘equivalence curve’ approach was first proposed by <xref ref-type="bibr" rid="bib24">Hauck and Anderson, 1986</xref>. We see that for realistic margins between 0 and 1, the proportion of replication successes remains below 50% for the conventional <inline-formula><mml:math id="inf102"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>α</mml:mi><mml:mo>=</mml:mo><mml:mn>0.05</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> level. To achieve a success rate of 11/15=73%, as was achieved with the non-significance criterion from the RPCB, unrealistic margins of <inline-formula><mml:math id="inf103"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi mathvariant="normal">Δ</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>2</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> are required. Changing the success criterion to a more lenient level (<inline-formula><mml:math id="inf104"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>α</mml:mi><mml:mo>=</mml:mo><mml:mn>0.1</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>) or a more stringent level (<inline-formula><mml:math id="inf105"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>α</mml:mi><mml:mo>=</mml:mo><mml:mn>0.01</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>) hardly changes the conclusion.</p><p>The bottom plot of <xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1</xref> shows a sensitivity analysis regarding the choice of the prior standard deviation and the Bayes factor threshold. It is uncommon to specify prior standard deviations larger than the unit-information standard deviation of 2, as this corresponds to the assumption of very large effect sizes under the alternative. However, to achieve replication success for a larger proportion of replications than the observed 1/15=7%, unreasonably large prior standard deviations have to be specified. For instance, a standard deviation of roughly 5 is required to achieve replication success in 50% of the replications at a lenient Bayes factor threshold of <inline-formula><mml:math id="inf106"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>γ</mml:mi><mml:mo>=</mml:mo><mml:mn>3</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>. The standard deviation needs to be almost 20 so that the same success rate 11/15=73% as with the non-significance criterion is achieved. The necessary standard deviations are even higher for stricter Bayes factor thresholds, such as <inline-formula><mml:math id="inf107"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>γ</mml:mi><mml:mo>=</mml:mo><mml:mn>6</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> or <inline-formula><mml:math id="inf108"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>γ</mml:mi><mml:mo>=</mml:mo><mml:mn>10</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>.</p><fig id="app1fig1" position="float"><label>Appendix 1—figure 1.</label><caption><title>Number of successful replications of original null results in the Reproducibility Project: Cancer Biology (RPCB) as a function of the margin <inline-formula><mml:math id="inf109"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> of the equivalence test (<inline-formula><mml:math id="inf110"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi mathvariant="normal">T</mml:mi><mml:mi mathvariant="normal">O</mml:mi><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">T</mml:mi></mml:mrow></mml:msub><mml:mo>≤</mml:mo><mml:mi>α</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> in both studies for <inline-formula><mml:math id="inf111"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>α</mml:mi><mml:mo>=</mml:mo><mml:mn>0.1</mml:mn><mml:mo>,</mml:mo><mml:mn>0.05</mml:mn><mml:mo>,</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>) or the standard deviation of the zero-mean normal prior distribution for the standardized mean difference (SMD) effect size under the alternative <italic>H</italic><sub>1</sub> of the Bayes factor test (<inline-formula><mml:math id="inf112"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>B</mml:mi><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mn>01</mml:mn></mml:mrow></mml:msub><mml:mo>≥</mml:mo><mml:mi>γ</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> in both studies for <inline-formula><mml:math id="inf113"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>γ</mml:mi><mml:mo>=</mml:mo><mml:mn>3</mml:mn><mml:mo>,</mml:mo><mml:mn>6</mml:mn><mml:mo>,</mml:mo><mml:mn>10</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>).</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92311-app1-fig1-v1.tif"/></fig></sec></app><app id="appendix-2"><title>Appendix 2</title><sec sec-type="appendix" id="s8"><title>Null results from the RPP and EPRP</title><p>Here, we perform equivalence test and Bayes factor analyses for the three original null results from the Reproducibility Project: Psychology (<xref ref-type="bibr" rid="bib15">Eastwick and Finkel, 2008</xref>; <xref ref-type="bibr" rid="bib56">Ranganath and Nosek, 2008</xref>; <xref ref-type="bibr" rid="bib58">Reynolds and Besner, 2008</xref>) and the original null result from the Reproducibility Project: Experimental Philosophy (<xref ref-type="bibr" rid="bib46">McCann, 2005</xref>). To enable comparison of effect sizes across different studies, both the RPP and the EPRP provided effect estimates as Fisher <italic>z</italic>-transformed correlations which we use in the following.</p><p><xref ref-type="fig" rid="app2fig1">Appendix 2—figure 1</xref> shows effect estimates with 90% confidence intervals, two-sided <italic>p</italic>-values for the null hypothesis that the effect size is zero, TOST <italic>p</italic>-values for a margin of <inline-formula><mml:math id="inf114"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mo>=</mml:mo><mml:mn>0.2</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> , and Bayes factors using a normal prior centered around zero with a standard deviation of 2. We see that all replications except the replication of <xref ref-type="bibr" rid="bib56">Ranganath and Nosek, 2008</xref> would be considered successful with the non-significance criterion, as the original and replication <italic>p</italic>-values are greater than 0.05. In all three cases, the Bayes factors also indicate substantial (<inline-formula><mml:math id="inf115"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>BF</mml:mi><mml:mrow><mml:mn>01</mml:mn></mml:mrow></mml:msub><mml:mo>&gt;</mml:mo><mml:mn>3</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>) to strong evidence (<inline-formula><mml:math id="inf116"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>BF</mml:mi><mml:mrow><mml:mn>01</mml:mn></mml:mrow></mml:msub><mml:mo>&gt;</mml:mo><mml:mn>10</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>) for the null hypothesis of no effect. Compared to the Bayes factors in the RPCB, the evidence is stronger, possibly due to the mostly larger sample sizes in the RPP and EPRP.</p><fig id="app2fig1" position="float"><label>Appendix 2—figure 1.</label><caption><title>Effect estimates on Fisher <italic>z</italic>-transformed correlation scale with a 90% confidence interval for the ‘null results’ and their replication studies from the Reproducibility Project: Psychology (RPP, <xref ref-type="bibr" rid="bib51">Open Science Collaboration, 2015</xref>) and the Experimental Philosophy Replicability Project (EPRP, <xref ref-type="bibr" rid="bib12">Cova et al., 2021</xref>).</title><p>The dashed gray line represents the value of no effect (<inline-formula><mml:math id="inf117"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>), while the dotted red lines represent the equivalence range with a margin of <inline-formula><mml:math id="inf118"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mo>=</mml:mo><mml:mn>0.74</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>. The <italic>p</italic>-value <inline-formula><mml:math id="inf119"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi mathvariant="normal">T</mml:mi><mml:mi mathvariant="normal">O</mml:mi><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> is the maximum of the two one-sided <italic>p</italic>-values for the null hypotheses of the effect being greater/less than <inline-formula><mml:math id="inf120"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mo>+</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf121"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mo>−</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>, respectively. The Bayes factor <inline-formula><mml:math id="inf122"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">B</mml:mi><mml:msub><mml:mi mathvariant="normal">F</mml:mi><mml:mrow><mml:mn>01</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> quantifies the evidence for the null hypothesis <inline-formula><mml:math id="inf123"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>H</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>:</mml:mo><mml:mi>z</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> against the alternative <inline-formula><mml:math id="inf124"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>H</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>:</mml:mo><mml:mi>z</mml:mi><mml:mo>≠</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> with normal prior centered around zero and standard deviation of 2 assigned to the effect size under <inline-formula><mml:math id="inf125"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>H</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92311-app2-fig1-v1.tif"/></fig><fig id="app2fig2" position="float"><label>Appendix 2—figure 2.</label><caption><title>Sensitivity analyses for the ‘null results’ and their replication studies from the Reproducibility Project: Psychology (RPP, <xref ref-type="bibr" rid="bib51">Open Science Collaboration, 2015</xref>) and the Experimental Philosophy Replicability Project (EPRP, <xref ref-type="bibr" rid="bib12">Cova et al., 2021</xref>).</title><p>The Bayes factor of the replication of <xref ref-type="bibr" rid="bib56">Ranganath and Nosek, 2008</xref> decreases very quickly and is only shown for a limited range.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92311-app2-fig2-v1.tif"/></fig><p>Interestingly, the opposite conclusion is reached when we analyze the data using an equivalence test with a margin of <inline-formula><mml:math id="inf126"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mo>=</mml:mo><mml:mn>0.2</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> (which may be considered liberal as it represents a small to medium effect based on the <xref ref-type="bibr" rid="bib10">Cohen, 1992</xref> convention). In this case, equivalence at the 5% level can only be established for the <xref ref-type="bibr" rid="bib56">Ranganath and Nosek, 2008</xref> original study and its replication simultaneously, as the confidence intervals from the other studies are too wide to be included in the equivalence range. Furthermore, the Ranganath and Nosek (2008) replication also illustrates the conceptual difference between testing for an <italic>exactly zero</italic> effect versus testing for an effect <italic>within an interval around zero</italic>. That is, the Bayes factor indicates no evidence for a zero effect (because the estimate is clearly not zero), but the equivalence test indicates evidence for a negligible effect (because the estimate is clearly within the equivalence range).</p><p>As before, the particular choices of the equivalence margin <inline-formula><mml:math id="inf127"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> for the equivalence test and prior standard deviation of the Bayes factor are debatable. We, therefore, report sensitivity analyses in <xref ref-type="fig" rid="app2fig2">Appendix 2—figure 2</xref> which show the TOST <italic>p</italic>-values and Bayes factors of original and replication studies for a range of margins and prior standard deviations, respectively. Apart from the <xref ref-type="bibr" rid="bib56">Ranganath and Nosek, 2008</xref> study pair, all studies require large margins of about <inline-formula><mml:math id="inf128"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi mathvariant="normal">Δ</mml:mi><mml:mo>=</mml:mo><mml:mn>0.4</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> to establish replication success at the 5% level (in the sense of original and replication TOST <italic>p</italic>-values being smaller than 0.05). On the other hand, in all but the <xref ref-type="bibr" rid="bib56">Ranganath and Nosek, 2008</xref> replication, the data provide substantial evidence for a null effect (<inline-formula><mml:math id="inf129"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>BF</mml:mi><mml:mrow><mml:mn>01</mml:mn></mml:mrow></mml:msub><mml:mo>&gt;</mml:mo><mml:mn>3</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>) for prior standard deviations of about one, while larger prior standard deviations of about three are required for the data to indicate strong evidence (<inline-formula><mml:math id="inf130"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>BF</mml:mi><mml:mrow><mml:mn>01</mml:mn></mml:mrow></mml:msub><mml:mo>&gt;</mml:mo><mml:mn>10</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>) for a null effect, whereas the data from the <xref ref-type="bibr" rid="bib56">Ranganath and Nosek, 2008</xref> replication provide very strong evidence against a null effect for all prior standard deviations considered.</p></sec></app><app id="appendix-3"><title>Appendix 3</title><sec sec-type="appendix" id="s9"><title>Technical details on Bayes factors</title><p>We assume that effect estimates are normally distributed around an unknown effect size <inline-formula><mml:math id="inf131"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>θ</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> with known variance equal to their squared standard error, i.e.,<disp-formula id="equ4"><mml:math id="m4"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mtable columnalign="right left right left right left right left right left right left" rowspacing="3pt" columnspacing="0em 2em 0em 2em 0em 2em 0em 2em 0em 2em 0em" displaystyle="true"><mml:mtr><mml:mtd><mml:msub><mml:mrow><mml:mover><mml:mi>θ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>∣</mml:mo><mml:mi>θ</mml:mi><mml:mo>∼</mml:mo><mml:mrow><mml:mi mathvariant="normal">N</mml:mi></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>for original (<inline-formula><mml:math id="inf132"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mi>o</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>) and replication (<inline-formula><mml:math id="inf133"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mi>r</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>). This framework is similar to meta-analysis and can be applied to many types of effect sizes and data (<xref ref-type="bibr" rid="bib64">Spiegelhalter et al., 2003</xref>, Section 2.4). We want to quantify the evidence for the null hypothesis that the effect size is equal to a null effect (<inline-formula><mml:math id="inf134"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>:</mml:mo><mml:mi>θ</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>, typically <inline-formula><mml:math id="inf135"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>) against the alternative hypothesis that the effect size is non-null (<inline-formula><mml:math id="inf136"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>:</mml:mo><mml:mi>θ</mml:mi><mml:mo>≠</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>). This requires specification of a prior distribution for the effect size under the alternative, and we will assume a normal prior <inline-formula><mml:math id="inf137"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>θ</mml:mi><mml:mspace width="thinmathspace"/><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mspace width="thinmathspace"/><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>∼</mml:mo><mml:mi mathvariant="normal">N</mml:mi><mml:mo>⁡</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>s</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> in the following. The Bayes factor based on an effect estimate is then given by the ratio of its likelihood under the null hypothesis to its marginal likelihood under the alternative hypothesis, i.e.,<disp-formula id="equ5"><mml:math id="m5"><mml:mrow><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msub><mml:mrow><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">F</mml:mi></mml:mrow><mml:mrow><mml:mn>01</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mi>θ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>∣</mml:mo><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mi>θ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>∣</mml:mo><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mstyle></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>=</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mi>θ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>∣</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:msubsup><mml:mo>∫</mml:mo><mml:mrow><mml:mo>−</mml:mo><mml:mi mathvariant="normal">∞</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo><mml:mi mathvariant="normal">∞</mml:mi></mml:mrow></mml:msubsup><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mi>θ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>∣</mml:mo><mml:mi>θ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mspace width="thinmathspace"/><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>θ</mml:mi><mml:mo>∣</mml:mo><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mspace width="thinmathspace"/><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mi>θ</mml:mi></mml:mrow></mml:mfrac></mml:mstyle></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mstyle displaystyle="true" scriptlevel="0"/></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:msqrt><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:msup><mml:mi>s</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:msubsup><mml:mi>σ</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mfrac></mml:msqrt><mml:mspace width="thinmathspace"/><mml:mi>exp</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mo>−</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mi>θ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mfrac><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mi>θ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mi>m</mml:mi><mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mi>s</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mfrac></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p><p>In the main analysis, we used a normal unit-information prior, that is, a normal distribution centered around the value of no effect (<inline-formula><mml:math id="inf138"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>m</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>) with a standard deviation<italic>s</italic> corresponding to the standard error of an SMD estimate based on one observation (<xref ref-type="bibr" rid="bib32">Kass and Wasserman, 1995</xref>). Assuming that the group means are normally distributed <inline-formula><mml:math id="inf139"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mover><mml:mi>X</mml:mi><mml:mo accent="false">¯</mml:mo></mml:mover><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>∼</mml:mo><mml:mi mathvariant="normal">N</mml:mi><mml:mo>⁡</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:msup><mml:mi>τ</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>n</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf140"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mover><mml:mi>X</mml:mi><mml:mo accent="false">¯</mml:mo></mml:mover><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>∼</mml:mo><mml:mi mathvariant="normal">N</mml:mi><mml:mo>⁡</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:msup><mml:mi>τ</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>n</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> with <inline-formula><mml:math id="inf141"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>n</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> the total sample size and <inline-formula><mml:math id="inf142"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>τ</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> the known data standard deviation, the distribution of the SMD is <inline-formula><mml:math id="inf143"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mtext>SMD</mml:mtext><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mover><mml:mi>X</mml:mi><mml:mo accent="false">¯</mml:mo></mml:mover><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mover><mml:mi>X</mml:mi><mml:mo accent="false">¯</mml:mo></mml:mover><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>τ</mml:mi><mml:mo>∼</mml:mo><mml:mi mathvariant="normal">N</mml:mi><mml:mo>⁡</mml:mo><mml:mo fence="false" stretchy="false">{</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>τ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mn>4</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>n</mml:mi><mml:mo fence="false" stretchy="false">}</mml:mo></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>. The standard error <inline-formula><mml:math id="inf144"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>σ</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> of the SMD based on one unit (<inline-formula><mml:math id="inf145"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>), is hence 2, meaning that the standard deviation of the unit-information prior is <inline-formula><mml:math id="inf146"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>s</mml:mi><mml:mo>=</mml:mo><mml:mn>2</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>.</p></sec></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92311.3.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Boonstra</surname><given-names>Philip</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>University of Michigan</institution><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Valuable</kwd></kwd-group></front-stub><body><p>This work provides a <bold>valuable</bold> contribution and assessment of what it means to replicate a null study finding, and what are the appropriate methods for doing so (apart from a rote p-value assessment). Through a <bold>convincing</bold> re-analysis of results from the Reproducibility Project: Cancer Biology using frequentist equivalence testing and Bayes factors, the authors demonstrate that even when reducing 'replicability success' to a single criterion, how precisely replication is measured may yield differing results. Less focus is directed to appropriate replication of non-null findings.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92311.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The goal of Pawel et al. is to provide a more rigorous and quantitative approach for judging whether or not an initial null finding (conventionally with p &gt;= 0.05) has been replicated by a second similarly null finding. They discuss important objections to relying on the qualitative significant/non-significant dichotomy to make this judgement. They present two complementary methods (one frequentist and the other Bayesian) which provide a superior quantitative framework for assessing the replicability of null findings.</p><p>Strengths:</p><p>Clear presentation; illuminating examples drawn from the well-known Reproducibility Project: Cancer Biology data set; R-code that implements suggested analyses. Using both methods as suggested provides a superior procedure for judging the replicability of null findings.</p><p>Weaknesses:</p><p>The frequentist and the Bayesian methods can be used to make binary assessments of an original finding and its replication. The authors clarify, though, that they can also be used to make continuous quantitative judgements about strength of evidence. I believe that most will use the methods in a binary fashion, but the availability of more nuanced assessments is welcome. This revision has addressed what I initially considered a weakness.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92311.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary and strengths:</p><list list-type="order"><list-item><p>The work provides significant insights because usually non-significant studies can be considered replicated by their null replications as well. The work discuss and provide data demonstrating that when analyzing studies with p &gt; 0.05 for the result to be replicated, equivalence tests and bayes factor approaches are more suitable, since studies can be underpowered even if replications use larger samples than their original studies in general. Non-significant p-values are highly expected even with 80% of power for a true effect.</p></list-item><list-item><p>The evidence used features methods and analyses more rigorous than current state-of-the-art research on replicability.</p></list-item></list><p>I am satisfied with the revisions made by the authors in response to my initial suggestions, as well as their subsequent responses to my observations throughout the reviewing process.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92311.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pawel</surname><given-names>Samuel</given-names></name><role specific-use="author">Author</role><aff><institution>University of Zurich</institution><addr-line><named-content content-type="city">Zurich</named-content></addr-line><country>Switzerland</country></aff></contrib><contrib contrib-type="author"><name><surname>Heyard</surname><given-names>Rachel</given-names></name><role specific-use="author">Author</role><aff><institution>University of Zurich</institution><addr-line><named-content content-type="city">Zurich</named-content></addr-line><country>Switzerland</country></aff></contrib><contrib contrib-type="author"><name><surname>Micheloud</surname><given-names>Charlotte</given-names></name><role specific-use="author">Author</role><aff><institution>University of Zurich</institution><addr-line><named-content content-type="city">Zurich</named-content></addr-line><country>Switzerland</country></aff></contrib><contrib contrib-type="author"><name><surname>Held</surname><given-names>Leonhard</given-names></name><role specific-use="author">Author</role><aff><institution>University of Zurich</institution><addr-line><named-content content-type="city">Zurich</named-content></addr-line><country>Switzerland</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>eLife assessment</bold></p><p>This work provides a valuable contribution and assessment of what it means to replicate a null study finding, and what are the appropriate methods for doing so (apart from a rote p-value assessment). Through a convincing re-analysis of results from the Reproducibility Project: Cancer Biology using frequentist equivalence testing and Bayes factors, the authors demonstrate that even when reducing 'replicability success' to a single criterion, how precisely replication is measured may yield differing results. Less focus is directed to appropriate replication of non-null findings.</p><p><bold>Reviewer #1 (Public Review):</bold></p><p>Summary:</p><p>The goal of Pawel et al. is to provide a more rigorous and quantitative approach for judging whether or not an initial null finding (conventionally with p ≥ 0.05) has been replicated by a second similarly null finding. They discuss important objections to relying on the qualitative significant/non-significant dichotomy to make this judgment. They present two complementary methods (one frequentist and the other Bayesian) which provide a superior quantitative framework for assessing the replicability of null findings.</p><p>Strengths:</p><p>Clear presentation; illuminating examples drawn from the well-known Reproducibility Project: Cancer Biology data set; R-code that implements suggested analyses. Using both methods as suggested provides a superior procedure for judging the replicability of null findings.</p><p>Weaknesses:</p><p>The proposed frequentist and the Bayesian methods both rely on binary assessments of an original finding and its replication. I'm not sure if this is a weakness or is inherent to making binary decisions based on continuous data.</p><p>For the frequentist method, a null finding is considered replicated if the original and replication 90% confidence intervals for the effects both fall within the equivalence range. According to this approach, a null finding would be considered replicated if p-values of both equivalences tests (original and replication) were, say, 0.049, whereas would not be considered replicated if, for example, the equivalence test of the original study had a p-value of 0.051 and the replication had a p-value of 0.001. Intuitively, the evidence for replication would seem to be stronger in the second instance. The recommended Bayesian approach similarly relies on a dichotomy (e.g., Bayes factor &gt; 1).</p></disp-quote><p>Thanks for the suggestions, we now emphasize more strongly in the “Methods for assessing replicability of null results” and “Conclusions” sections that both TOST p-values and Bayes factors are quantitative measures of evidence that do not require dichotomization into “success” or “failure”.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review):</bold></p><p>Summary:</p><p>The study demonstrates how inconclusive replications of studies initially with p &gt; 0.05 can be and employs equivalence tests and Bayesian factor approaches to illustrate this concept. Interestingly, the study reveals that achieving a success rate of 11 out of 15, or 73%, as was accomplished with the non-significance criterion from the RPCB (Reproducibility Project: Cancer Biology), requires unrealistic margins of Δ &gt; 2 for equivalence testing.</p><p>Strengths:</p><p>The study uses reliable and shareable/open data to demonstrate its findings, sharing as well the code for statistical analysis. The study provides sensitivity analysis for different scenarios of equivalence margin and alfa level, as well as for different scenarios of standard deviations for the prior of Bayes factors and different thresholds to consider. All analysis and code of the work is open and can be replicated. As well, the study demonstrates on a case-by-case basis how the different criteria can diverge, regarding one sample of a field of science: preclinical cancer biology. It also explains clearly what Bayes factors and equivalence tests are.</p><p>Weaknesses:</p><p>It would be interesting to investigate whether using Bayes factors and equivalence tests in addition to p-values results in a clearer scenario when applied to replication data from other fields. As mentioned by the authors, the Reproducibility Project: Experimental Philosophy (RPEP) and the Reproducibility Project: Psychology (RPP) have data attempting to replicate some original studies with null results. While the RPCB analysis yielded a similar picture when using both criteria, it is worth exploring whether this holds true for RPP and RPEP. Considerations for further research in this direction are suggested. Even if the original null results were excluded in the calculation of an overall replicability rate based on significance, sensitivity analyses considering them could have been conducted. The present authors can demonstrate replication success using the significance criteria in these two projects with initially p &lt; 0.05 studies, both positive and non-positive.</p><p>Other comments:</p><list list-type="bullet"><list-item><p>Introduction: The study demonstrates how inconclusive replications of studies initially with p &gt; 0.05 can be and employs equivalence tests and Bayesian factor approaches to illustrate this concept. Interestingly, the study reveals that achieving a success rate of 11 out of 15, or 73%, as was accomplished with the non-significance criterion from the RPCB (Reproducibility Project: Cancer Biology), requires unrealistic margins of Δ &gt; 2 for equivalence testing.</p></list-item></list><list list-type="bullet"><list-item><p>Overall picture vs. case-by-case scenario: An interesting finding is that the authors observe that in most cases, there is no substantial evidence for either the absence or the presence of an effect, as evidenced by the equivalence tests. Thus, using both suggested criteria results in a picture similar to the one initially raised by the paper itself. The work done by the authors highlights additional criteria that can be used to further analyze replication success on a case-by-case basis, and I believe that this is where the paper's main contributions lie. Despite not changing the overall picture much, I agree that the p-value criterion by itself does not distinguish between (1) a situation where the original study had low statistical power, resulting in a highly inconclusive non-significant result that does not provide evidence for the absence of an effect and (2) a scenario where the original study was adequately powered, and a non-significant result may indeed provide some evidence for the absence of an effect when analyzed with appropriate methods. Equivalence testing and Bayesian factor approaches are valuable tools in both cases.</p></list-item></list><p>Regarding the 0.05 threshold, the choice of the prior distribution for the SMD under the alternative H1 is debatable, and this also applies to the equivalence margin. Sensitivity analyses, as highlighted by the authors, are helpful in these scenarios.</p></disp-quote><p>Thank you for the thorough review and constructive feedback. We have added an additional “Appendix C: Null results from the RPP and EPRP” that shows equivalence testing and Bayes factor analyses for the RPP and EPRP null results.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Public Review):</bold></p><p>Summary:</p><p>The paper points out that non-significance in both the original study and a replication does not ensure that the studies provide evidence for the absence of an effect. Also, it can not be considered a &quot;replication success&quot;. The main point of the paper is rather obvious. It may be that both studies are underpowered, in which case their non-significance does not prove anything. The absence of evidence is not evidence of absence! On the other hand, statistical significance is a confusing concept for many, so some extra clarification is always welcome.</p><p>One might wonder if the problem that the paper addresses is really a big issue. The authors point to the &quot;Reproducibility Project: Cancer Biology&quot; (RPCB, Errington et al., 2021). They criticize Errington et al. because they &quot;explicitly defined null results in both the original and the replication study as a criterion for replication success.&quot; This is true in a literal sense, but it is also a little bit uncharitable. Errington et al. assessed replication success of &quot;null results&quot; with respect to 5 criteria, just one of which was statistical (non-)significance.</p><p>It is very hard to decide if a replication was &quot;successful&quot; or not. After all, the original significant result could have been a false positive, and the original null-result a false negative. In light of these difficulties, I found the paper of Errington et al. quite balanced and thoughtful. Replication has been called &quot;the cornerstone of science&quot; but it turns out that it's actually very difficult to define &quot;replication success&quot;. I find the paper of Pawel, Heyard, Micheloud, and Held to be a useful addition to the discussion.</p><p>Strengths:</p><p>This is a clearly written paper that is a useful addition to the important discussion of what constitutes a successful replication.</p><p>Weaknesses:</p><p>To me, it seems rather obvious that non-significance in both the original study and a replication does not ensure that the studies provide evidence for the absence of an effect. I'm not sure how often this mistake is made.</p></disp-quote><p>Thanks for the feedback. We do not have systematic data on how often the mistake of confusing absence of evidence with evidence of absence has been made in the replication context, but we do know that it has been made in at least three prominent large-scale replication projects (the RPP, RPEP, RPCB). We therefore believe that there is a need for our article.</p><p>Moreover, we agree that the RPCB provided a nuanced assessment of replication success using five different criteria for the original null results. We emphasize this now more in the “Introduction” section. However, we do not consider our article as “a little bit uncharitable” to the RPCB, as we discuss all other criteria used in the RPCB and note that our intent is not to diminish the important contributions of the RPCB, but rather to build on their work and provide constructive recommendations for future researchers. Furthermore, in response to comments made by Reviewer #2, we have added an additional “Appendix B: Null results from the RPP and EPRP” that shows equivalence testing and Bayes factor analyses for null results from two other replication projects, where the same issue arises.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>The authors may wish to address the dichotomy issue I raise above, either in the analysis or in the discussion.</p></disp-quote><p>Thank you, we now emphasize that Bayes factors and TOST p-values do not need to be dichotomized but can be interpreted as quantitative measures of evidence, both in the “Methods for assessing replicability of null results” and the “Conclusions” sections.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>Given that, here follow additional suggestions that the authors should consider in light of the manuscript's word count limit, to avoid confusing the paper's main idea:</p><p>1. Referencing: Could you reference the three interesting cases among the 15 RPCB null results (specifically, the three effects from the original paper #48) where the Bayes factor differs qualitatively from the equivalence test?</p></disp-quote><p>We now explicitly cite the original and replication study from paper #48.</p><disp-quote content-type="editor-comment"><p>1. Equivalence testing: As the authors state, only 4 out of the 15 study pairs are able to establish replication success at the 5% level, in the sense that both the original and the replication 90% confidence intervals fall within the equivalence range. Among these 4, two (Paper #48, Exp #2, Effect #5 and Paper #48, Exp #2, Effect #6) were initially positive with very low p-values, one (Paper #48, Exp #2, Effect #4) had an initial p of 0.06 and was very precisely estimated, and the only one in which equivalence testing provides a clearer picture of replication success is Paper #41, Exp #2, Effect #1, which had an initial p-value of 0.54 and a replication p-value of 0.05. In this latter case (or in all these ones), one might question whether the &quot;liberal&quot; equivalence range of Δ = 0.74 is the most appropriate. As the authors state, &quot;The post-hoc specification of equivalence margins is controversial.&quot;</p></disp-quote><p>We agree that the post hoc choice of equivalence ranges is a controversial issue. The margins define an equivalence region where effect sizes are considered practically negligible, and we agree that in many contexts SMD = 0.74 is a large effect size that is not practically negligible. We therefore present sensitivity analyses for a wide range of margins. However, we do not think that the choice of this margin is more controversial for the mentioned studies with low p-values than for other studies with greater p-values, since the question of whether a margin plausibly encodes practically negligible effect sizes is not related to the observed p-value of a study. Nevertheless, for the new analyses of the RPP and EPRP data in Appendix B, we have added additional sensitivity analyses showing how the individual TOST p-values and Bayes factors vary as a function of the margin and the prior standard deviation. We think that these analyses provide readers with an even more transparent picture regarding the implications of the choice of these parameters than the “project-wise” sensitivity analyses in Appendix A.</p><disp-quote content-type="editor-comment"><p>1. Bayes factor suggestions: For the Bayes factor approach, it would be interesting to discuss examples where the BF differs slightly. This is likely to occur in scenarios where sample sizes differ significantly between the original study and replication. For example, in Paper #48, Exp #2 and Effect #4, the initial p is 0.06, but the BF is 8.1. In the replication, the BF dramatically drops to &lt; 1/1000, as does the p-value. The initial evidence of 8.1 indicates some evidence for the absence of an effect, but not strong evidence (&quot;strong evidence for H0&quot;), whereas a p-value of 0.06 does not lead to such a conclusion; instead, it favors H1. It would be interesting if the authors discussed other similar cases in the paper. It's worth noting that in Paper #5, Exp #1, Effect #3, the replication p-value is 0.99, while the BF01 is 2.4, almost indicating &quot;moderate&quot; evidence for H0, even though the p-value is inconclusive.</p></disp-quote><p>We agree that some of the examples nicely illustrate conceptual differences between p-values and Bayes factors, e.g., how they take into account sample size and effect size. As methodologists, we find these aspects interesting ourselves, but we think that emphasizing them is beyond the scope of the paper and would distract eLife readers from the main messages.</p><p>Concerning the conceptual differences between Bayes factors and TOST p-values, we already discuss a case where there are qualitative differences in more detail (original paper #48). We added another discussion of this phenomenon in the Appendix C as it also occurs for the replication of Ranganath and Nosek (2008) that was part of the RPP.</p><disp-quote content-type="editor-comment"><p>1. p-values, magnitude and precision: It's noteworthy to emphasize, if the authors decide to discuss this, that the p-value is influenced by both the effect's magnitude and its precision, so in Paper #9, Exp #2, Effect #6, BF01 = 4.1 has a higher p-value than a BF01 = 2.3 in its replication. However, there are cases where both p-values and BF agree. For example, in Paper #15, Exp #2, Effect #2, both the original and replication studies have similar sample sizes, and as the p-value decreases from p = 0.95 to p = 0.23, BF01 decreases from 5.1 (&quot;moderate evidence for H0&quot;) to 1.3 (region of &quot;Absence of evidence&quot;), moving away from H0 in both cases. This also occurs in Paper #24, Exp #3, Effect #6.</p></disp-quote><p>We appreciate the suggestions but, as explained before, think that the message of our paper is better understood without additional discussion of more general differences between p-values and Bayes factors.</p><disp-quote content-type="editor-comment"><p>1. The grey zone: Given the above topic, it is important to highlight that in the &quot;Absence of evidence grey zone&quot; for the null hypothesis, for example, in Paper #5, Exp #1, Effect #3 with a p = 0.99 and a BF01 = 2.4 in the replication, BF and p-values reach similar conclusions. It's interesting to note, as the authors emphasize, that Dawson et al. (2011), Exp #2, Effect #2 is an interesting example, as the p-value decreases, favoring H1, likely due to the effect's magnitude, even with a small sample size (n = 3 in both original and replications). Bayes factors are very close to one due to the small sample sizes, as discussed by the authors.</p></disp-quote><p>We appreciate the constructive comments. We think that the two examples from Dawson et al. (2011) and Goetz et al. (2011) already nicely illustrate absence of evidence and evidence of absence, respectively, and therefore decided not to discuss additional examples in detail, to avoid redundancy.</p><disp-quote content-type="editor-comment"><p>1. Using meta-analytical results (?): For papers from RPCB, comparing the initial study with the meta-analytical results using Bayes factor and equivalence testing approaches (thus, increasing the sample size of the analysis, but creating dependency of results since the initial study would affect the meta-analytical one) could change the conclusions. This would be interesting to explore in initial studies that are replicated by much larger ones, such as: Paper #9, Exp #2, Effect #6; Goetz et al. (2011), Exp #1, Effect #1; Paper #28, Exp #3, Effect #3; Paper #41, Exp #2, Effect #1; and Paper #47, Exp #1, Effect #5).</p></disp-quote><p>Thank you for the suggestion. We considered adding meta-analytic TOST p-values and Bayes factors before, but decided that Figure 3 and the results section are already quite technical, so adding more analyses may confuse more than help. Nevertheless, these meta-analytic approaches are discussed in the “Conclusions” section.</p><disp-quote content-type="editor-comment"><p>1. Other samples of fields of science: It would be interesting to investigate whether using Bayes factors and equivalence tests in addition to p-values results in a clearer scenario when applied to replication data from other fields. As mentioned by the authors, the Reproducibility Project: Experimental Philosophy (RPEP) and the Reproducibility Project: Psychology (RPP) have data attempting to replicate some original studies with null results. While the RPCB analysis yielded a similar picture when using both criteria, it is worth exploring whether this holds true for RPP and RPEP. Considerations for further research in this direction are suggested. Even if the original null results were excluded in the calculation of an overall replicability rate based on significance, sensitivity analyses considering them could have been conducted. The present authors can demonstrate replication success using the significance criteria in these two projects with initially p &lt; 0.05 studies, both positive and non-positive.</p></disp-quote><p>Thank you for the excellent suggestion. We added an Appendix B where the null results from the RPP and EPRP are analyzed with our proposed approaches. The results are also discussed in the “Results” and “Conclusions” sections.</p><disp-quote content-type="editor-comment"><p>1. Other approaches: I am curious about the potential impact of using an approach based on equivalence testing (as described in <ext-link ext-link-type="uri" xlink:href="https://arxiv.org/abs/2308.09112">https://arxiv.org/abs/2308.09112</ext-link>). It would be valuable if the authors could run such analyses or reference the mentioned work.</p></disp-quote><p>Thank you. We were unaware of this preprint. It seems related to the framework proposed by Stahel W. A. (2021) New relevance and significance measures to replace p-values. PLoS ONE 16(6): e0252991.<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0252991">https://doi.org/10.1371/journal.pone.0252991</ext-link></p><p>We now cite both papers in the discussion.</p><disp-quote content-type="editor-comment"><p>1. Additional evidence: There is another study in which replications of initially p &gt; 0.05 studies with p &gt; 0.05 replications were also considered as replication successes. You can find it here: <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2022.05.31.22275810v2">https://www.medrxiv.org/content/10.1101/2022.05.31.22275810v2</ext-link>. Although it involves a small sample of initially p &gt; 0.05 studies with already large sample sizes, the work is currently under consideration for publication in PLOS ONE, and all data and materials can be accessed through OSF (links provided in the work).</p></disp-quote><p>Thank you for sharing this interesting study with us. We feel that it is beyond the scope of the paper to include further analyses as there are already analyses of the RPCB, RPP, and EPRP null results. However, we will keep this study in mind for future analysis, especially since all data are openly available.</p><disp-quote content-type="editor-comment"><p>1. Additional evidence 02: Ongoing replication projects, such as the Brazilian Reproducibility Initiative (BRI) and The Sports Replication Centre (<ext-link ext-link-type="uri" xlink:href="https://ssreplicationcentre.com/">https://ssreplicationcentre.com/</ext-link>), continue to generate valuable data. BRI is nearing completion of its results, and it promises interesting data for analyzing replication success using p-values, equivalence regions, and Bayes factor approaches.</p></disp-quote><p>We now cite these two initiatives as examples of ongoing replication projects in the introduction. Similarly as for your last point, we think that it is beyond the scope of the paper to include further analyses as there are already analyses of the RPCB, RPP, and EPRP null results.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Recommendations For The Authors):</bold></p><p>I have no specific recommendations for the authors.</p></disp-quote><p>Thank you for the constructive review.</p><disp-quote content-type="editor-comment"><p><bold>Reviewing Editor (Recommendations For the Authors):</bold></p><p>I recognize that it was suggested to the authors by the previous Reviewing Editor to reduce the amount of statistical material to be made more suitable for a non-statistical audience, and so what I am about to say contradicts advice you were given before. But, with this revised version, I actually found it difficult to understand the particulars of the construction of the Bayes Factors and would have appreciated a few more sentences on the underlying models that fed into the calculations. In my opinion, the provided citations (e.g., Dienes Z. 2014. Using Bayes to get the most out of non-significant results) did not provide sufficient background to warrant a lack of more technical presentation here.</p></disp-quote><p>Thank you for the feedback. We added a new “Appendix C: Technical details on Bayes factors” that provides technical details on the models, priors, and calculations underlying the Bayes factors.</p></body></sub-article></article>